Reports

Royal Bank of Canada (RBC) delivered a strong Q1 2025 performance with net income of $5.1 billion, up 43% YoY, and diluted EPS of $3.54, up 42% YoY. Adjusted net income was $5.3 billion, reflecting a 29% YoY increase. Total revenue grew 24% to $16.74 billion, driven by higher net interest income and fee-based revenue. The bank maintained a robust CET1 ratio of 13.2%, supporting capital growth and shareholder returns.

• Net income surged 43% YoY to $5.1 billion, driven by growth across business segments.
• Diluted EPS increased 42% YoY to $3.54, while adjusted EPS rose 27% to $3.62.

TD Bank Group delivered stable earnings in Q1 2025, with total revenue of $14.05 billion, up 2% YoY. Adjusted net income stood at $3.62 billion, while adjusted EPS was $2.02. Higher provisions for credit losses and governance-related expenses weighed on profitability. The bank maintained a robust Common Equity Tier 1 (CET1) capital ratio of 13.1%, demonstrating financial strength.

• Total revenue increased 2% YoY to $14.05 billion, driven by growth in commercial banking and wealth management.
• Adjusted EPS was $2.02, reflecting stable earnings performance.

EOG Resources posted Q4 2024 revenue of $5.59 billion, a decline from $6.36 billion in Q4 2023. Net income was $1.25 billion, down from $1.99 billion in the prior year. Adjusted non-GAAP EPS stood at $2.74, while GAAP EPS was $2.23. The company reported crude oil production of 494.6 MBod, and total crude oil equivalent volumes of 1,095.7 MBoed. Free cash flow was $1.28 billion, and the company returned nearly $1.5 billion to shareholders through dividends and share repurchases.

• Revenue declined 12.1% year-over-year to $5.59 billion.
• Net income decreased 37.1% to $1.25 billion.

Dell Technologies reported a strong Q4 FY25 with revenue growing 7% YoY to $23.93 billion. GAAP EPS was $2.15, while non-GAAP EPS reached $2.68. Operating income increased by 40% to $2.16 billion, driven by significant growth in the Infrastructure Solutions Group. The company also announced an 18% increase in its annual dividend and a $10 billion share repurchase authorization.

• Revenue grew 7% YoY to $23.93 billion.
• GAAP EPS was $2.15, and non-GAAP EPS was $2.68.

Autodesk reported strong Q4 FY25 results with a 12% YoY increase in revenue to $1.64 billion. GAAP EPS was $1.40, and non-GAAP EPS was $2.29. Operating income grew to $366 million, with an operating margin of 22%. The company also announced a workforce reduction plan affecting 1,350 employees.

• Total revenue increased by 12% to $1.64 billion.
• GAAP EPS was $1.40, while non-GAAP EPS reached $2.29.

CIBC reported revenue of CAD 7.281 billion for Q1 2025, reflecting a 17% year-over-year increase. Adjusted net income rose by 23% to CAD 2.179 billion, while adjusted diluted EPS increased by 22% to CAD 2.20. The bank's strong capital position, reflected in a CET1 ratio of 13.5%, supports future growth and resilience.

• Revenue increased 17% year-over-year to CAD 7.281 billion.
• Adjusted net income grew by 23% to CAD 2.179 billion.

Monster Beverage reported Q4 2024 revenue of $1.81 billion, up 4.7% YoY. GAAP EPS decreased to $0.28, while non-GAAP EPS remained at $0.38. Net income fell 26.2% to $270.7 million, while operating income declined 12.2% to $381.2 million. The Monster Energy Drinks segment continued to grow, while the Alcohol Brands segment saw a slight decline in sales.

• Total revenue increased 4.7% YoY to $1.81 billion.
• GAAP EPS dropped to $0.28, while non-GAAP EPS held at $0.38.

Vistra delivered strong Q4 2024 results, reporting significant year-over-year growth in net income and adjusted EBITDA. The company benefited from the Energy Harbor acquisition and increased revenues from nuclear production tax credits.

• Net income of $490 million, compared to a loss of $184 million in Q4 2023.
• Revenue grew 21.82% YoY, reaching $4.431 billion.

Haleon achieved organic revenue growth of 6.8% in Q4 2024, driven by a combination of price and volume/mix improvements. The company's total revenue for the quarter reached £2.85 billion. Adjusted diluted EPS was 4.48p. The company saw continued strength in its Oral Health and Vitamins, Minerals, and Supplements (VMS) segments, while Pain Relief and Respiratory Health faced some headwinds.

• Organic revenue growth in Q4 2024 was 6.8%, with price contributing 3.7% and volume/mix 3.1%.
• Adjusted diluted EPS for Q4 2024 was 4.48p.

Eni's Q4 2024 results showed a decline in profitability, with proforma adjusted EBIT at €2.7 billion, down 28% YoY. The company reported net profit of €305 million, a significant drop from the prior year. Hydrocarbon production remained stable at 1.72 million boe/d, supported by organic project ramp-ups and acquisitions. Despite the challenging macroeconomic environment, the company continued its strategic investments, including expanding its LNG business and renewable energy capacity.

• Proforma adjusted EBIT declined 28% YoY to €2.7 billion due to weaker crude prices and refining margins.
• Net profit dropped to €305 million, impacted by lower upstream realizations and higher tax rates.

Argenx achieved Q4 2024 revenue of $761.2 million, driven by strong VYVGART product sales. Net income reached $774.2 million, reflecting a significant improvement from the prior year’s loss. Diluted EPS was $11.79, while adjusted EPS was $0.93. The company benefited from a one-time tax gain of $725 million, contributing to profitability.

• Revenue grew to $761.2 million in Q4 2024, up from $417.8 million in Q4 2023.
• Net income was $774.2 million, reversing a loss of $99.2 million in Q4 2023.

Hafnia generated revenue of $352.8 million in Q4 2024, a decline from the previous year. Net income dropped to $79.6 million, impacted by lower tanker rates and increased crude sector competition. EPS for the quarter was $0.16. The company distributed $14.6 million in dividends and executed share buybacks, bringing total shareholder returns to 80% of net profit.

• Q4 2024 revenue declined to $352.8 million from $472.0 million in Q4 2023.
• Net income fell to $79.6 million, down from $176.4 million in Q4 2023.

Warner Bros Discovery (WBD) saw strong Direct-to-Consumer (DTC) growth in Q4 2024, with a 20% increase in DTC subscribers and significant Adjusted EBITDA improvements. The company generated $2.7 billion in operating cash flow and $2.4 billion in free cash flow. Networks revenue declined 4% year-over-year, while Studios revenue grew 15%. Net income was reported at -$494 million, including restructuring expenses and content fair value step-up charges.

• Total revenue of $10.03 billion, down 2% year-over-year.
• DTC revenue grew 5% to $2.65 billion, driven by 6.4M new subscribers.

NetApp reported revenue of $1.64 billion for Q3 FY25, a 2% increase year-over-year. Net income was $299 million, down from $313 million in Q3 FY24. The company maintained strong growth in its cloud storage segment, with first-party and marketplace cloud storage revenue increasing over 40%. Non-GAAP EPS was $1.91, while GAAP EPS was $1.44.

• Revenue increased 2% year-over-year to $1.64 billion.
• Net income decreased to $299 million from $313 million in Q3 FY24.

Liberty Media's Q4 2024 results reflect a decrease in Formula One Group's revenue and operating income, offset by growth in corporate and other revenues. The fair value of Live Nation investment increased, contributing to Liberty Live Group's assets. Overall, the company is focusing on strategic priorities for 2025, including the MotoGP acquisition and Liberty Live structure.

• Formula 1 fan attendance reached 6.5 million in 2024, up 9% compared to 2023.
• Several race promotion agreements were renewed, extending key races through 2031.

Telefonica reported Q4 2024 revenue of €10.70 billion, reflecting a year-over-year increase of 5.4%. Adjusted net income stood at €425 million, down 41.8% from the prior year, while adjusted EPS was €0.06. Operating income declined by 33.8% to -€511 million. The company maintained strong cash flow, with free cash flow reaching €1.52 billion in the quarter.

• Revenue increased by 5.4% year-over-year to €10.70 billion in Q4 2024.
• Net income dropped by 41.8% to €425 million, reflecting impairment impacts.

Edison International's Q4 2024 net income declined to $340 million from $378 million in the prior year. Adjusted EPS also dropped to $1.05 from $1.28. The decline was primarily due to increased operational and interest expenses, although higher authorized revenue provided some offset.

• Q4 2024 net income was $340 million, down from $378 million in Q4 2023.
• Adjusted EPS declined to $1.05 from $1.28 year-over-year.

BeiGene posted total revenue of $1.13 billion for Q4 2024, reflecting a 78% increase year-over-year. The company narrowed its GAAP operating loss and achieved positive non-GAAP operating income. The success was primarily driven by BRUKINSA, which led the market in new CLL patient starts in the U.S. and expanded in Europe.

• Total revenue for Q4 2024 was $1.13 billion, a 78% increase from Q4 2023.
• Net loss per share improved to $0.11 from $0.27 in Q4 2023.

Natera's Q4 2024 revenue increased by 53% year-over-year to $476.1 million, primarily due to higher product revenue. The company processed 792,800 tests in the quarter, up 26.5% from Q4 2023. Gross margin improved to 62.9%, reflecting cost efficiencies. Net loss narrowed to $53.8 million from $78.0 million in the previous year.

• Q4 2024 revenue grew 53% to $476.1 million, driven by strong product sales.
• Gross margin improved to 62.9% from 51.4% in Q4 2023.

Pembina Pipeline Corporation reported Q4 2024 revenue of CAD 2.15 billion, an increase from CAD 1.84 billion in Q4 2023. Net income was CAD 572 million, while adjusted EBITDA reached a record CAD 1.25 billion. Higher pipeline and facility volumes, along with improved NGL margins, contributed to the company's strong performance.

• Q4 2024 revenue increased to CAD 2.15 billion from CAD 1.84 billion in Q4 2023.
• Net income for the quarter was CAD 572 million, down from CAD 698 million in Q4 2023.

Erie Indemnity delivered robust financial results in Q4 2024, with net income rising to $152.0 million and operating income increasing by 31.7% year-over-year. Management fee revenue from policy issuance and renewal services saw a notable 16.1% growth. Investment income also improved, contributing to overall profitability.

• Net income increased 37.1% YoY to $152.0 million.
• Operating income rose 31.7% YoY, reaching $167.3 million.

Hormel Foods reported Q1 FY25 net sales of $2.99 billion, with adjusted EPS of $0.35. Operating income declined, impacted by higher input costs and a challenging macroeconomic environment. The company reaffirmed its fiscal 2025 guidance, with continued focus on strategic initiatives.

• Net sales of $2.99 billion, a slight decline of 0.3% from last year.
• Adjusted diluted earnings per share of $0.35, compared to $0.41 last year.

Evergy reported Q4 2024 GAAP earnings of $78.2 million, or $0.34 per share, compared to $58.0 million, or $0.25 per share, for Q4 2023. Adjusted earnings (non-GAAP) for Q4 2024 were $80.6 million, or $0.35 per share, compared to $61.1 million, or $0.27 per share, in Q4 2023. The company reaffirmed its 2025 GAAP and adjusted EPS guidance of $3.92 to $4.12.

• Q4 2024 GAAP EPS was $0.34, compared to $0.25 in Q4 2023.
• Q4 2024 adjusted EPS (non-GAAP) was $0.35, compared to $0.27 in Q4 2023.

Rocket Lab posted a record-breaking Q4 2024 with revenue surging 121% YoY to $132.4 million. The company reported a net loss of $52.3 million, while operating losses stood at $51.5 million. Gross profit increased to $36.8 million, and cash and cash equivalents rose to $271 million. The company achieved a record 16 Electron launches in 2024, a 60% increase YoY.

• Total revenue grew 121% YoY to $132.4 million.
• Net loss widened to $52.3 million from $50.5 million a year ago.

Duolingo reported strong Q4 2024 results with revenue growing 39% YoY to $209.6 million. GAAP EPS was $0.32, while non-GAAP EPS was not provided. Operating income increased to $13.88 million, and free cash flow surged to $87.8 million, reflecting a 42% free cash flow margin. Paid subscribers reached 9.5 million, up 43% YoY, driving record total bookings of $271.6 million.

• Total revenue grew 39% YoY to $209.6 million.
• Paid subscribers reached 9.5 million, a 43% YoY increase.

Viatris posted Q4 2024 revenue of $3.52 billion, reflecting an 8% decline year-over-year. The company reported a GAAP net loss of $516.5 million and adjusted EPS of $0.54. While the Greater China segment showed positive growth, other geographic regions and product categories experienced declines.

• Total revenue for Q4 2024 was $3.52 billion, down 8% year-over-year.
• GAAP net loss of $516.5 million, with an adjusted EPS of $0.54.

Solventum delivered a solid quarter with total sales reaching $2.074 billion, marking a 1.9% increase year-over-year. GAAP diluted EPS stood at $0.17, while adjusted EPS reached $1.41. The company generated $219 million in operating cash flow and achieved $92 million in free cash flow. Organic sales growth was led by MedSurg and Dental Solutions segments.

• Total sales increased 1.9% YoY to $2.074 billion.
• GAAP EPS was $0.17, while adjusted EPS reached $1.41.

Norwegian Cruise Line Holdings delivered a record Q4 2024 performance, with total revenue reaching $2.1 billion, up 6% YoY. Net income surged to $254.5 million from a loss in Q4 2023, driven by strong onboard spending and cost efficiencies. Adjusted EBITDA grew 30% to $468.2 million, exceeding guidance. The company reported an occupancy rate of 100.8%, indicating strong demand across its fleet.

• Total revenue increased 6% YoY to $2.1 billion, driven by strong onboard spending.
• Net income improved significantly to $254.5 million, compared to a loss in Q4 2023.

Liberty Broadband reported its Q4 2024 results, noting progress on its merger with Charter and plans to spin off GCI. GCI's revenue increased by 5% in Q4, driven by business revenue growth, while consumer revenue remained flat. Operating income increased, but Adjusted OIBDA decreased slightly.

• Liberty Broadband is progressing with its merger with Charter, expecting to close on June 30, 2027, and received shareholder approval.
• The company is actively working towards spinning off its GCI business in the summer of 2025.

The J.M. Smucker Co. reported a 2% decline in net sales for Q3 FY25, primarily due to supply chain disruptions and lower volume/mix. The company posted a net loss per diluted share of $6.22, reflecting significant impairment charges related to the Sweet Baked Snacks reporting unit. Adjusted EPS increased by 5% to $2.61. Free cash flow declined to $151.3 million, compared to $249.6 million in the prior year.

• Net sales decreased 2% to $2.19 billion, impacted by supply chain disruptions.
• Reported net loss of $6.22 per share due to impairment charges.

Elastic delivered a solid Q3 FY25 performance, achieving total revenue of $382 million, reflecting a 17% year-over-year increase. Elastic Cloud revenue grew by 26% year-over-year, highlighting strong demand for its cloud offerings. The company reported a GAAP operating loss of $5 million, while non-GAAP operating income reached $64 million. Free cash flow improved to $99 million, underscoring strong cash generation.

• Total revenue grew 17% YoY to $382 million.
• Elastic Cloud revenue increased 26% YoY to $180 million.

MasTec delivered strong Q4 2024 results, reporting revenue of $3.4 billion, a 3.8% increase year-over-year. The company achieved GAAP net income of $84.7 million and adjusted net income of $124 million, highlighting improved profitability. Adjusted EBITDA stood at $270.9 million, with a margin improvement of 110 basis points. The company ended the quarter with a record $14.3 billion backlog, reflecting continued demand in its key business segments.

• Total revenue increased 3.8% YoY to $3.4 billion.
• GAAP EPS was $0.95, while adjusted EPS reached $1.44.

CubeSmart's Q4 2024 results reflected continued challenges in the self-storage sector, with same-store net operating income declining 3.7% year-over-year due to increased expenses and lower revenue. Total revenue increased slightly to $1.07 billion, driven by growth in property management fees. The company maintained a high occupancy rate of 89.3% and improved financial flexibility with strong cash flow and acquisitions.

• Reported total revenue of $1.07 billion, up slightly year-over-year.
• GAAP EPS was $0.45, while adjusted FFO per share was $0.68.

AAON reported a 2.9% decline in revenue for Q4 2024, with total sales reaching $297.7 million. The company faced headwinds from a regulated refrigerant transition and weaker nonresidential construction activity, impacting sales in the AAON Oklahoma segment. However, strong demand in the BASX brand for data center cooling solutions helped offset some losses. Net income dropped 47.5% year-over-year to $24.7 million, while EPS decreased to $0.30 from $0.56 in Q4 2023.

• Q4 2024 revenue decreased by 2.9% year-over-year to $297.7 million.
• Net income fell by 47.5% to $24.7 million due to higher costs and lower sales.

Vertex delivered strong revenue growth in Q4 2024, with total revenue increasing by 15.2% year-over-year to $178.5 million. Software subscriptions contributed $152.6 million, while cloud revenues grew 27.0% to $76.9 million. However, the company posted a net loss of $67.8 million due to increased operating expenses and acquisition-related costs. Non-GAAP net income was $25.5 million, with an adjusted EBITDA of $38.1 million.

• Total revenue grew by 15.2% year-over-year to $178.5 million.
• Net loss was $67.8 million, compared to net income of $15.3 million in Q4 2023.

Mosaic's Q4 2024 revenue declined to $2.82 billion, reflecting lower sales volumes and pricing pressures in potash and Mosaic Fertilizantes. The company reported a net income of $169 million, down from $365 million in the prior year. Adjusted EPS stood at $0.45, while adjusted EBITDA reached $594 million. The company is optimistic about improved production and cost reductions in 2025.

• Total revenue declined 10.6% YoY to $2.82 billion.
• GAAP EPS was $0.53, while adjusted EPS was $0.45.

Donaldson Company, Inc. reported Q2 FY25 revenue of $870 million, down 0.8% year-over-year, with adjusted EPS rising 2.5% to $0.83. Operating margin declined slightly due to restructuring charges, but adjusted operating margin improved. Aftermarket, Aerospace & Defense, and Life Sciences segments showed growth, while Off-Road and On-Road declined. The company reaffirmed its FY25 guidance with expectations of record EPS.

• Revenue declined by 0.8% year-over-year to $870 million, impacted by currency headwinds.
• Adjusted EPS increased by 2.5% to $0.83, while GAAP EPS declined to $0.79.

Teleflex Incorporated reported Q4 2024 revenue of $795.4 million, up 2.8% year-over-year, with adjusted EPS rising 15.1% to $3.89. GAAP EPS declined to $(2.95) due to a $240 million non-cash goodwill impairment charge. The Interventional and Surgical segments showed strong growth, while Interventional Urology declined. The company reaffirmed its FY25 guidance with expectations for continued revenue growth and adjusted EPS improvements.

• Revenue grew 2.8% year-over-year to $795.4 million, driven by strong Interventional and Surgical segments.
• GAAP EPS declined to $(2.95) due to a $240 million non-cash goodwill impairment charge.

Bath & Body Works reported Q4 2024 net sales of $2.788 billion, a 4.3% decline due to an extra week in the prior year. EPS was $2.09, down from $2.55 last year. Operating income fell to $678 million, while net income dropped to $453 million. Despite these declines, results exceeded company guidance.

• Net sales declined by 4.3% year-over-year, impacted by an extra week in 2023.
• EPS was $2.09, surpassing company guidance.

Embraer delivered a solid Q4 2024, with revenue increasing 17% YoY to $2.31 billion. Adjusted EBIT reached $265.1 million, with an 11.5% margin, and adjusted net income was $173.0 million, up significantly from $77.6 million in Q4 2023. The company reported strong aircraft deliveries and a record backlog of $26.3 billion, reflecting sustained demand across its business units.

• Revenue increased 17% YoY to $2.31 billion, reaching the high end of guidance.
• Adjusted EBIT margin expanded to 11.5%, supported by higher aircraft deliveries and strong operating leverage.

EchoStar's Q4 2024 revenue declined to $3.97 billion from $4.16 billion in Q4 2023, primarily due to continued Pay-TV and broadband subscriber losses. The company posted a net income of $335.23 million, a sharp improvement from the previous year's loss. Wireless subscriber growth and lower churn contributed positively, while Pay-TV continued to see subscriber declines.

• Total revenue decreased by 4.7% year-over-year to $3.97 billion.
• Net income improved to $335.23 million from a loss of $2.03 billion in Q4 2023.

ADT delivered solid Q4 2024 results, with total revenue increasing by 8% year-over-year to $1.26 billion. Net income from continuing operations reached $197 million, while adjusted EPS was $0.20. The company achieved record-high recurring monthly revenue and maintained strong customer retention. ADT also improved free cash flow, reflecting its strategic focus on operational efficiency and profitability.

• Total revenue grew by 8% year-over-year to $1.26 billion.
• GAAP net income from continuing operations reached $197 million.

Starwood Property Trust's Q4 2024 revenue reached $496.67 million, driven by interest income from loans and investment securities. Net income for the quarter was $51.6 million, significantly impacted by a $52.4 million credit loss provision. Distributable earnings stood at $166.7 million, with a GAAP EPS of $0.15 and a non-GAAP EPS of $0.48.

• Total revenue for Q4 2024 reached $496.67 million.
• Net income for the quarter was $51.6 million, reflecting credit loss provisions.

Life Time's Q4 2024 revenue grew by 18.7% year-over-year to $663.3 million, driven by increased membership dues and in-center revenue. Net income rose 57.0% to $37.2 million, while Adjusted EBITDA increased by 28.5% to $177.0 million. The company ended the quarter with 812,062 memberships and a record-high average center revenue per membership.

• Total revenue increased 18.7% to $663.3 million.
• Net income improved 57.0% to $37.2 million.

Cytokinetics' Q4 2024 revenue surged to $16.9 million, up from $1.7 million a year ago, primarily driven by a $15 million upfront payment from Corxel related to aficamten. However, research and development expenses rose to $93.6 million, reflecting the company's continued investment in clinical trials. Net loss widened to $150 million, translating to a GAAP EPS of -$1.26. The company ended the quarter with a strong cash position of $1.2 billion.

• Total revenue increased to $16.9 million, primarily due to milestone payments.
• GAAP EPS was -$1.26, reflecting higher R&D and commercial readiness costs.

Nuvalent reported its fourth quarter and full year 2024 financial results, highlighting pipeline advancements, the reiteration of key milestones, and the implementation of global Expanded Access Programs for zidesamtinib and neladalkib.

• Pivotal data is expected in 2025 for both TKI pre-treated ROS1-positive and TKI pre-treated ALK-positive NSCLC populations.
• The first NDA submission is planned for mid-year 2025, targeting potential first approval in 2026 for zidesamtinib in the TKI pre-treated ROS1-positive NSCLC population.

Installed Building Products posted a record Q4 2024 revenue of $750.2 million, a 4.1% year-over-year increase. Net income rose 3.1% to $66.9 million, with adjusted net income reaching $80.6 million. The installation segment drove growth, supported by acquisitions and increased residential activity. The company maintained strong profitability despite a slight decline in gross margin.

• Total revenue reached a record $750.2 million, up 4.1% year-over-year.
• Net income increased by 3.1% to $66.9 million.

ACI Worldwide's Q4 2024 revenue decreased 4.9% year-over-year to $453.0 million, impacted by a decline in license revenue. Net income dropped 19.6% to $98.6 million, while adjusted EBITDA fell 24.8% to $157.7 million. SaaS and PaaS recurring revenue remained stable at $223.5 million, and new ARR bookings increased 22.2% year-over-year. The company expects 7-9% revenue growth in 2025.

• Total revenue declined 4.9% to $453.0 million.
• Net income decreased 19.6% to $98.6 million.

Main Street Capital delivered a solid Q4 2024, with total investment income reaching $140.4 million, marking a 9% year-over-year increase. The company reported net investment income of $90.4 million, translating to an EPS of $1.02. Return on equity stood at an impressive 25.4%. The firm declared a supplemental dividend and expanded its private loan and lower middle market portfolios, reinforcing its strong financial position.

• Total investment income grew 9% YoY to $140.4 million.
• GAAP EPS was $1.02, with a net increase in assets of $174.2 million.

Cool Company Ltd. generated total operating revenues of $84.6 million in Q4 2024, with a net income of $29.4 million. Adjusted EBITDA came in at $55.3 million, slightly higher than Q3 2024. Despite lower charter rates, strong term charters and cost efficiencies supported profitability. The company opted not to declare a dividend due to prevailing market conditions.

• Total operating revenues reached $84.6 million, up from $82.4 million in Q3 2024.
• Net income surged to $29.4 million, benefiting from a mark-to-market gain on interest rate swaps.

SoundHound AI delivered an exceptional Q4 2024 performance, achieving record revenue of $34.5 million, a 101% increase compared to the previous year. Despite strong topline growth, the company reported a GAAP net loss of $258.6 million, largely impacted by non-cash fair value adjustments. Adjusted EBITDA stood at -$16.8 million, reflecting continued investment in AI-driven voice solutions. The company ended the quarter with a strong cash position of $198 million and no debt.

• Revenue surged 101% YoY to $34.5 million, exceeding expectations.
• GAAP EPS was -$0.69, while non-GAAP EPS was -$0.05.

Bloom Energy achieved record revenue of $572.39 million in Q4 2024, a 60.42% YoY increase, driven by strong demand for products and services. Net income surged to $104.80 million, and the company generated $484.23 million in operating cash flow. The company improved its gross margin to 38.3% and maintained strong financial momentum heading into 2025.

• Record Q4 revenue of $572.39 million, up 60.42% YoY.
• Net income surged to $104.80 million, up from $4.51 million in Q4 2023.

Nexstar Media Group achieved record net revenue of $1.49 billion in Q4 2024, reflecting a 14.1% year-over-year increase, mainly due to a surge in political advertising revenue. Net income reached $229 million, more than doubling from the prior year. Adjusted EBITDA rose by 39.9% to $628 million, while free cash flow increased by 67.8% to $411 million. The company continued reducing debt and returning capital to shareholders.

• Total net revenue reached $1.49 billion, up 14.1% year-over-year.
• Political advertising revenue surged to $254 million, offsetting declines in non-political ad sales.

Assured Guaranty reported Q4 2024 net income of $18 million, or $0.35 per share, a sharp decline from Q4 2023. Adjusted operating income was $66 million, or $1.27 per share. The company saw lower net investment income and higher loss expenses, affecting profitability. Gross written premiums were $186 million for the quarter.

• Net income declined to $18 million due to foreign exchange losses and lower fair value gains.
• Adjusted operating income was $66 million, compared to $338 million in Q4 2023.

Millicom posted revenue of $1.43 billion in Q4 2024, a 3.2% year-over-year decline due to lower B2B sales in Panama. However, operating profit surged 63.4% to $373 million, driven by efficiency gains. Net income improved to $31 million from a $63 million loss in Q4 2023. Free cash flow jumped to $213 million, reflecting disciplined capital spending and lower spectrum payments.

• Revenue declined 3.2% year-over-year to $1.43 billion.
• Operating profit increased 63.4% to $373 million.

Technip Energies delivered solid Q4 2024 results with revenue of €1.88 billion, a 17.2% increase year-over-year. Net income grew to €110.4 million, and adjusted EBIT reached €139.1 million. The company secured significant contracts, including Net Zero Teesside Power and GranMorgu FPSO, reinforcing its leadership in energy and decarbonization projects.

• Q4 2024 revenue increased 17.2% year-over-year to €1.88 billion.
• Net income grew to €110.4 million from €86.7 million in Q4 2023.

Arcosa, Inc. delivered a solid Q4 2024 performance, with revenue increasing by 14% to $666.2 million. However, the company posted a net loss of $7.7 million due to acquisition-related expenses and higher depreciation costs. Adjusted EBITDA rose by 52% to $128.3 million, driven by improved margins and strong performance in key segments. Free cash flow surged to $199.2 million, reflecting a significant increase in operating cash flow.

• Revenue grew 14% year-over-year to $666.2 million, driven by acquisitions and organic growth.
• Net loss of $7.7 million primarily due to acquisition costs and higher depreciation.

RadNet delivered strong Q4 2024 results with revenue rising 13.5% to $477.1 million. Adjusted EPS improved to $0.22, reflecting operational efficiency and strategic investments. The company saw an 8.0% increase in procedural volumes, including double-digit growth in MRI, CT, and PET/CT scans. Cash reserves surged to $740 million, positioning RadNet well for future expansion.

• Total revenue increased 13.5% year-over-year to $477.1 million.
• Adjusted EPS rose to $0.22 from $0.15 in Q4 2023.

Six Flags delivered a solid Q4 2024 performance with revenue of $687 million, a significant increase due to the merger with legacy Cedar Fair. The company reported a net loss of $264 million, primarily due to merger-related costs and tax provisions. Adjusted EBITDA reached $209 million, reflecting operational efficiency and cost synergies.

• Q4 2024 revenue increased to $687 million, driven by the merger and higher in-park spending.
• Attendance surged to 10.7 million guests, with 5 million from legacy Six Flags parks.

American Healthcare REIT reported a GAAP net loss of $31.8 million in Q4 2024, equating to a loss of $0.21 per share. However, the company achieved strong Same-Store NOI growth of 21.6% for the quarter, driven by the senior housing operating properties (SHOP) segment, which grew 66.6%. The company also raised $120.2 million in equity through its at-the-market (ATM) program.

• GAAP net loss of $31.8 million, or $0.21 per share.
• Same-Store NOI grew 21.6% year-over-year, led by SHOP and ISHC segments.

Verra Mobility's Q4 2024 revenue increased by 5% year-over-year to $221.5 million, driven by growth in the Commercial Services and Government Solutions segments. However, the company reported a net loss of $66.7 million, primarily due to a $97.1 million goodwill impairment in the Parking Solutions segment. Adjusted EPS improved to $0.33 from $0.24 in Q4 2023, and adjusted EBITDA grew to $102.0 million.

• Total revenue increased by 5% year-over-year to $221.5 million.
• Net loss of $66.7 million due to a $97.1 million goodwill impairment.

Verona Pharma reported Q4 2024 revenue of $36.6 million, primarily from the commercial launch of Ohtuvayre, its novel inhaled COPD therapy. The company posted a net loss of $33.8 million due to increased R&D and SG&A expenses related to commercialization and ongoing clinical trials. Cash and cash equivalents increased to $399.8 million, strengthening Verona’s financial position as it advances its pipeline programs.

• Q4 2024 revenue reached $36.6 million, driven by strong Ohtuvayre sales.
• Net loss increased to $33.8 million due to commercialization and R&D investments.

GEO Group's Q4 2024 revenue was $607.7 million, nearly flat compared to the previous year. However, net income dropped to $15.5 million from $25.2 million in Q4 2023 due to higher administrative and restructuring costs. Adjusted EBITDA was $108.0 million, down from $129.0 million in Q4 2023. The company continues to focus on deleveraging, expecting to reduce net debt by up to $175 million in 2025.

• Revenue remained stable at $607.7 million, compared to $608.3 million in Q4 2023.
• Net income fell to $15.5 million, impacted by restructuring and higher administrative costs.

ICU Medical's Q4 2024 revenue rose to $629.8 million, reflecting strong demand across all segments, particularly in Vital Care. However, the company posted a GAAP net loss of $23.8 million, with an EPS of $(0.97), impacted by increased operating expenses. Adjusted EPS improved to $2.11, and adjusted EBITDA grew to $105.5 million, driven by better gross margins and higher revenue.

• Total revenue increased 7.1% year-over-year to $629.8 million.
• GAAP net loss widened to $23.8 million from $17.1 million in Q4 2023.

Acushnet Holdings Corp. reported Q4 2024 net sales of $445.2 million, representing a 7.8% increase year-over-year. The company also significantly reduced its net loss to $1.1 million, an improvement of $25.7 million compared to the prior-year period. Adjusted EBITDA improved to $12.4 million from a loss of $1.5 million in Q4 2023.

• Q4 2024 net sales increased 7.8% to $445.2 million.
• Net loss reduced to $1.1 million from $26.8 million in Q4 2023.

Acadia Healthcare's Q4 2024 revenue increased by 4.2% year-over-year to $774.2 million, driven by higher patient volumes and growth in same-facility revenue. However, net income declined to $32.6 million, impacted by increased operating expenses and facility-related costs. Adjusted EPS came in at $0.64, while adjusted EBITDA totaled $153.1 million, reflecting a $14.3 million professional liability reserve adjustment and a $5.0 million impact from facility closures.

• Total revenue increased by 4.2% year-over-year to $774.2 million.
• Same-facility revenue grew by 4.7%, driven by a 3.2% increase in patient days.

Global Business Travel Group, Inc. (GBTG) reported Q4 2024 revenue of $591 million, an 8% increase year-over-year, driven by growth in business travel and professional services. Adjusted EBITDA rose 39% to $110 million, with a margin expansion to 19%. Net loss improved significantly to $14 million, down from $46 million in the prior-year quarter.

• Q4 2024 revenue increased 8% year-over-year to $591 million.
• Adjusted EBITDA grew 39% to $110 million, with a margin of 19%.

International Bancshares Corporation reported a strong fourth quarter for 2024, with net income increasing by 8.2% and diluted earnings per common share increasing by 8.1% compared to the same period in 2023. Total assets, net loans, and deposits also saw increases.

• Net income for Q4 2024 was approximately $115.1 million, an 8.2% increase from Q4 2023.
• Diluted earnings per common share for Q4 2024 were $1.85, an 8.1% increase from Q4 2023.

Hilton Grand Vacations reported Q4 2024 revenue of $1.284 billion, up from $1.019 billion in the prior year. Net income attributable to stockholders was $20 million, a sharp decline from $68 million in Q4 2023, impacted by a $49 million net construction deferral. EPS dropped to $0.19 from $0.62, while adjusted EPS fell to $0.49 from $1.01. The company repurchased 3.2 million shares during the quarter for $125 million.

• Total revenue increased 26% year-over-year, reaching $1.284 billion.
• EPS fell to $0.19 due to construction deferrals and lower net income.

Nelnet's Q4 2024 revenue reached $401.41 million, reflecting strong performance in its core segments. GAAP net income was $63.2 million ($1.73 per share), a significant improvement from a net loss in Q4 2023. Excluding derivative market value adjustments, net income was $52.7 million ($1.44 per share). Loan Servicing and Systems revenue grew to $138.0 million, while Nelnet Bank expanded its loan and investment portfolio to $757.0 million. The company remains well-positioned for continued diversification and expansion in 2025.

• GAAP net income reached $63.2 million, compared to a net loss of $7.9 million in Q4 2023.
• Loan Servicing and Systems revenue grew to $138.0 million, up from $128.8 million a year ago.

Scholar Rock reported its full year 2024 financial results, highlighting the submission of the apitegromab BLA, progress towards MAA submission, upcoming data readouts, and a strong cash position.

• Submitted apitegromab U.S. Biologics License Application (BLA) for patients with spinal muscular atrophy in January 2025; U.S. launch anticipated in 4Q 2025.
• Remain on track to submit European Union marketing authorisation application (MAA) in 1Q 2025.

Sotera Health reported a decrease in net revenues for the fourth quarter of 2024, falling by 6.5% to $290 million. Net income also decreased to $12 million, or $0.04 per diluted share, compared to $39 million, or $0.14 per diluted share, in the same quarter of the previous year. Adjusted EBITDA saw a decrease of 8.3% to $153 million, and Adjusted EPS was $0.21, a decrease of $0.02 per diluted share.

• Net revenues decreased by 6.5% to $290 million compared to Q4 2023.
• Net income was $12 million, or $0.04 per diluted share, down from $39 million, or $0.14 per diluted share, in Q4 2023.

Archer Aviation maintained a strong liquidity position with over $1 billion in cash and raised additional capital. The company is progressing toward commercial deployment with its Midnight aircraft, securing Abu Dhabi Aviation as its first customer. Net loss increased in Q4, but spending remained stable. Archer also started production of its first Midnight aircraft at its ARC facility.

• Archer announced its 'Launch Edition' commercialization program with Abu Dhabi Aviation as its first customer.
• The company maintained a strong liquidity position with over $1 billion in cash and cash equivalents.

Tecnoglass reported Q4 2024 revenue of $239.6 million, up 23.1% year-over-year, supported by strong growth in multi-family and single-family residential segments. Net income rose to $47.0 million, with EPS increasing to $1.00 from $0.77 last year. Adjusted EPS reached $1.05, while Adjusted EBITDA climbed to $79.2 million, reflecting improved margins and pricing. The company also expanded its backlog to a record $1.1 billion, providing strong visibility for future growth.

• Revenue grew 23.1% year-over-year, reaching a quarterly record of $239.6 million.
• EPS increased to $1.00 from $0.77 in Q4 2023, driven by margin expansion.

Payoneer delivered strong Q4 2024 results with a 17% revenue increase to $261.7 million. Net income declined by 33% to $18.2 million, while adjusted EBITDA rose 21% to $63.3 million. Total transaction volume reached $22.5 billion, an 18% increase year-over-year, supported by robust B2B and marketplace segment growth. The company continues to focus on expanding its financial stack and regulatory capabilities.

• Revenue increased 17% year-over-year to $261.7 million.
• Transaction volume grew 18% to $22.5 billion.

Cogent Communications reported Q4 2024 revenue of $252.3 million, a 7.3% decline year-over-year. Despite lower revenue, EBITDA improved to $41.9 million, with an EBITDA margin expansion to 16.6%. Net loss was $43.3 million, narrowing from a net income of $200.2 million in Q4 2023, which included a one-time gain from the Sprint acquisition.

• Q4 2024 revenue declined 7.3% year-over-year to $252.3 million.
• EBITDA increased to $41.9 million, up from $6.0 million in Q4 2023.

Avidity Biosciences reported a net loss of $102.257 million for Q4 2024, with collaboration revenue of $2.973 million. The company ended 2024 with approximately $1.5 billion in cash, cash equivalents, and marketable securities, positioning it for significant milestones in 2025, including preparing for its first BLA submission.

• Avidity Biosciences reported a net loss of $102.257 million for the fourth quarter of 2024.
• Collaboration revenue for Q4 2024 was $2.973 million, primarily from a partnership with Bristol Myers Squibb.

PTC Therapeutics reported total Q4 2024 revenue of $213 million, driven by solid product sales and royalty revenue. The company's net loss for the quarter was $65.9 million, showing improvement from the prior year. PTC successfully met all clinical and regulatory milestones in 2024 and maintains a strong cash position exceeding $1.1 billion.

• Total revenue for Q4 2024 was $213.2 million, a decline from $307.1 million in Q4 2023.
• Net loss for Q4 2024 improved to $65.9 million from $155.8 million in Q4 2023.

Alkami Technology, Inc. achieved strong revenue growth of 25.6% year-over-year, reaching $89.7 million. The company's net loss narrowed to $7.6 million, improving from a $12.7 million loss in the prior-year quarter. Adjusted EPS came in at $0.11, and Adjusted EBITDA increased significantly to $10.2 million, up from $3.1 million in Q4 2023.

• Revenue increased 25.6% year-over-year to $89.7 million.
• GAAP net loss improved to $7.6 million from $12.7 million in the previous year.

Crinetics Pharmaceuticals reported a net loss of $80.6 million for Q4 2024, compared to a net loss of $60.1 million in Q4 2023. The company had no reported revenues for the quarter. Research and development expenses increased significantly, primarily due to higher personnel costs and expanded clinical activities. Crinetics remains well-funded, with $1.4 billion in cash, expected to support operations into 2029.

• Net loss widened to $80.6 million from $60.1 million in the previous year.
• Research and development expenses increased to $66.6 million from $45.6 million in Q4 2023.

dLocal's Q4 2024 results showed continued strong growth in Total Payment Volume (TPV), which increased by 51% year-over-year to $7.7 billion. Revenue reached $204 million, marking a 9% increase year-over-year. Net income came in at $29.7 million, while adjusted EBITDA improved by 16% to $56.9 million. The company maintained strong cash reserves of $425 million, positioning itself for future investments and expansion.

• Total Payment Volume (TPV) increased 51% year-over-year to $7.7 billion.
• Revenue grew 9% year-over-year to $204 million.

Globalstar's Q4 2024 revenue increased 17% year-over-year to $61.2 million, driven by strong growth in wholesale capacity services. Adjusted EBITDA rose 21% to $30.4 million, while the net loss widened to $50.2 million, primarily due to a non-cash loss on debt extinguishment and foreign currency fluctuations. The company maintained a strong cash position with $391.2 million in cash and equivalents.

• Total revenue grew 17% year-over-year to $61.2 million.
• Adjusted EBITDA increased 21% to $30.4 million.

Perrigo's Q4 2024 revenue declined by 1.6% year-over-year to $1.14 billion due to divested businesses and currency impact, while adjusted EPS increased to $0.93 from $0.86 in the prior year. Adjusted operating income grew by 16% to $194 million, benefiting from cost-saving initiatives. The company's net loss widened to $41 million due to restructuring and litigation-related charges, but strong performance in infant formula sales helped offset declines in other categories.

• Net sales decreased 1.6% year-over-year to $1.14 billion.
• Adjusted EPS increased by 8.1% to $0.93.

DoubleVerify's Q4 2024 revenue increased 11% year-over-year to $190.6 million, driven by growth in activation, measurement, and supply-side customer segments. Net income was $23.4 million, while adjusted EBITDA reached $73.8 million with a record 39% margin. The company continued to expand globally, with strong demand for CTV measurement and social media verification services.

• Total revenue increased 11% year-over-year to $190.6 million.
• Net income was $23.4 million, with an adjusted EBITDA margin of 39%.

AvePoint closed 2024 with an outstanding fourth quarter, achieving significant revenue growth and improved profitability. SaaS revenue continued to be a strong driver, and the company reported positive GAAP and non-GAAP operating income for both the quarter and the full year.

• Total revenue for Q4 2024 increased by 20% year-over-year to $89.2 million.
• SaaS revenue for Q4 2024 grew by 43% year-over-year to $64.8 million.

Denali Therapeutics reported a net loss of $114.8 million for the fourth quarter of 2024, compared to a net loss of $119.5 million in the same period last year. The company had no collaboration revenue for the quarter. Total research and development expenses decreased, while general and administrative expenses increased.

• Net loss for Q4 2024 was $114.8 million, an improvement from $119.5 million in Q4 2023.
• No collaboration revenue was reported for Q4 2024, consistent with Q4 2023.

Hayward Holdings reported a 17% increase in net sales to $327.1 million and a 76% increase in net income to $54.7 million for the fourth quarter of fiscal year 2024. The company's performance was driven by higher volumes, increased net price, and the favorable impact from acquisitions. Adjusted EBITDA increased by 30% to $98.7 million, and diluted EPS increased by 79% to $0.25.

• Net sales increased 17% year-over-year to $327.1 million.
• Net income increased 76% year-over-year to $54.7 million.

First Advantage reported Q4 2024 revenues of $307.1 million and a net loss of $(100.4) million, which includes $97.1 million of expenses related to the Sterling acquisition. Adjusted net income was $30.2 million, and adjusted EBITDA was $82.9 million. Full year 2025 guidance includes revenues of $1.5 billion to $1.6 billion, adjusted EBITDA of $410 million to $450 million, adjusted net income of $152 million to $182 million, and adjusted diluted earnings per share of $0.86 to $1.03.

• Revenues for Q4 2024 reached $307.1 million.
• Net loss for Q4 2024 was $(100.4) million, including $97.1 million in expenses related to the Sterling acquisition.

Warby Parker reported a 17.8% increase in net revenue for Q4 2024, reaching $190.6 million. The company's GAAP net loss improved to $6.9 million, and Adjusted EBITDA Margin increased to 7.3%. They also announced a partnership with Target Corporation to launch Warby Parker shop-in-shops in select Target locations in 2025.

• Net revenue increased by 17.8% year-over-year to $190.6 million.
• Gross margin improved to 54.1% compared to 53.8% in the prior year.

PENN Entertainment reported solid Q4 2024 results, marked by revenue growth at properties unaffected by new supply and substantial improvements in the Interactive segment, driven by online casino growth and disciplined promotional strategies. The company intends to repurchase at least $350 million of shares in 2025.

• Property-level operating results showed nearly 3% year-over-year revenue growth for properties not impacted by new supply.
• The Interactive segment saw significant year-over-year improvements in revenue and Adjusted EBITDA due to disciplined promotional strategies and online Casino business growth.

LifeStance Health Group reported a 16% increase in fourth-quarter revenue, reaching $325.5 million. The company's clinician base grew by 12% to 7,424, with visit volumes increasing by 14% to 2.0 million. Net loss for the quarter was $7.1 million, while net cash from operations was $62.3 million. Adjusted EBITDA stood at $32.8 million, and free cash flow was $56.0 million.

• Fourth quarter revenue increased by 16% to $325.5 million.
• Clinician base grew by 12% to 7,424 clinicians.

Xenon Pharmaceuticals reported a net loss of $65.7 million for Q4 2024, an increase from $44.7 million in Q4 2023, primarily due to higher research and development expenses. The company anticipates having sufficient cash to fund operations into 2027.

• Net loss for Q4 2024 was $65.7 million, compared to $44.7 million for the same period in 2023.
• Research and development expenses increased to $59.5 million in Q4 2024 from $41.1 million in Q4 2023.

Alignment Healthcare, Inc. announced strong fourth quarter and full-year 2024 results, with health plan membership significantly increasing by 58.6% year-over-year to 189,100. The company achieved its first full year of positive adjusted EBITDA as a public company, driven by operating leverage and strong medical benefits ratio performance. Total revenue for Q4 2024 was $701.2 million, a 50.7% increase year-over-year.

• Health plan membership reached approximately 189,100 as of December 31, 2024, marking a 58.6% year-over-year increase and surpassing year-end expectations.
• The company achieved its first full year of positive adjusted EBITDA as a public company, demonstrating improved operating leverage and strong medical benefits ratio performance.

Vericel reported a strong fourth quarter and full-year 2024, with total net revenue for the quarter increasing by 16% to $75.4 million. The company saw growth in MACI and Burn Care revenues, along with a record gross margin of 78% and net income growth of 52% to $19.8 million.

• Total net revenue for Q4 2024 reached $75.4 million, a 16% increase year-over-year.
• MACI net revenue grew by 21% compared to the prior year and 53% versus the prior quarter, reaching $68.3 million.

TEGNA Inc. reported a 20% increase in total company revenue to $871 million for the fourth quarter, driven primarily by political advertising strength. GAAP net income attributable to TEGNA Inc. was $181 million, with GAAP earnings per diluted share at $1.11. The company returned $20 million to shareholders through dividends and $50 million through share repurchases during the quarter.

• Total company revenue increased 20% to $871 million, driven by political advertising.
• Political advertising revenue totaled $187 million for the fourth quarter.

Zai Lab reported a strong fourth quarter and full year 2024, marked by a 66% increase in Q4 revenue to $109.1 million and a 50% increase in full-year revenue to $399.0 million. The company saw a 45% decrease in loss from operations for the quarter and is targeting $2 billion in revenue by 2028 and profitability in Q4 2025.

• Total revenues grew 66% year-over-year for the fourth quarter of 2024, reaching $109.1 million.
• Loss from operations decreased 45% year-over-year for the fourth quarter of 2024, amounting to $67.9 million.

Tidewater Inc. announced a strong fourth quarter for 2024, with revenue increasing to $345.1 million and net income reaching $36.9 million. The company's average day rate saw a substantial increase to $22,236 per day, reflecting favorable market conditions and strategic fleet high-grading.

• Revenue for Q4 2024 increased to $345.1 million, up from $302.7 million in Q4 2023.
• Net income for Q4 2024 was $36.9 million, compared to $37.7 million in Q4 2023, impacted by foreign exchange loss.

Medical Properties Trust reported a net loss of ($0.69) per share and Normalized Funds from Operations (NFFO) of $0.18 per share for the fourth quarter of 2024. The results include impairments and fair market value adjustments related to Prospect Medical Group and PHP Holdings. The company completed a $2.5 billion senior secured notes offering and amended its line of credit, addressing debt maturities through 2026.

• Net loss of ($0.69) per share and NFFO of $0.18 per share for Q4 2024.
• Completed a $2.5 billion senior secured notes offering to repay debt maturities through October 2026.

Novocure reported a 21% increase in total net revenues for Q4 2024, reaching $161.3 million. The company achieved key objectives including Optune Lua's FDA approval and positive Phase 3 trial results. However, the net loss for the quarter was $65.9 million, or $0.61 per share.

• Total net revenues for the quarter were $161.3 million, a 21% increase year-over-year.
• Optune Lua received FDA approval for metastatic non-small cell lung cancer, with commercial rollout underway.

Privia Health reported strong Q4 2024 results, exceeding guidance ranges with a 4.6% increase in total revenue to $460.9 million and a 55.0% increase in net income to $4.4 million. The company's implemented providers increased by 11.2% year-over-year, and adjusted EBITDA grew by 44.0% to $24.9 million.

• Total revenue increased by 4.6% to $460.9 million.
• Net income rose by 55.0% to $4.4 million.

California Water Service Group reported strong operational and financial performance in 2024, with a key milestone being the filing of the 2024 California GRC, which includes investments to provide a safe and sustainable water supply to customers.

• Filed the 2024 California GRC, including investments for a safe and sustainable water supply.
• Increased cash position to $95.7 million from $85.0 million in 2023.

Playtika Holding Corp. reported Q4 2024 revenue of $650.3 million, a 1.9% increase year-over-year, and DTC revenue of $174.6 million, an 8.0% increase year-over-year. However, the company experienced a net loss of $16.7 million. The average daily paying users increased by 10.8% year over year.

• Revenue increased by 1.9% year-over-year, reaching $650.3 million.
• DTC platforms revenue increased by 8.0% year-over-year, totaling $174.6 million.

Kymera Therapeutics reported collaboration revenues of $7.4 million for Q4 2024. The company's research and development expenses were $71.8 million, and general and administrative expenses were $16.3 million. Net loss for the quarter was $70.8 million. The company's cash and cash equivalents totaled $851 million as of December 31, 2024.

• KT-621 Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025.
• KT-621 Phase 1b trial in atopic dermatitis (AD) patients expected to initiate in 2Q25 with data in 4Q25, followed by two parallel Phase 2b trials in AD and asthma starting in 4Q25 and 1Q26, respectively.

Janux Therapeutics had an exceptional year in 2024, demonstrating substantial clinical activity with JANX007 and significantly strengthening its financial position with $1.03 billion in cash, cash equivalents, and short-term investments. The company reported a net loss of $20.2 million for the quarter, with research and development expenses increasing to $20.8 million.

• Positive updated interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer was presented in December 2024, showing high PSA response rates and encouraging anti-tumor activity.
• Janux reported $1.03 billion in cash, cash equivalents, and short-term investments as of December 31, 2024, a substantial increase from the previous year.

Strategic Education, Inc. reported a 2.9% increase in revenue for the fourth quarter of 2024, reaching $311.5 million compared to $302.7 million in the same period in 2023. However, net income decreased to $25.3 million from $39.1 million, and diluted earnings per share fell to $1.05 from $1.63 year-over-year. The U.S. Higher Education segment saw a revenue decrease, while the Education Technology Services segment experienced significant growth.

• Revenue increased by 2.9% to $311.5 million.
• Net income decreased to $25.3 million from $39.1 million.

ICF reported a strong fourth quarter in 2024, with revenue increasing by 4% to $496.3 million and net income rising by 11% to $24.6 million. Diluted EPS was $1.30, up 12% year-over-year. The company also achieved a quarterly book-to-bill ratio of 1.02, with contract awards totaling $504 million.

• Fourth quarter revenue increased 4% to $496.3 million, driven by strong demand from commercial energy clients.
• Net income for the fourth quarter was $24.6 million, an 11% increase year-over-year, with diluted EPS at $1.30, up 12%.

Clover Health demonstrated differentiated clinical and financial results in 2024, driven by its technology-first physician empowerment model and home care arm. The company achieved strong Adjusted EBITDA profitability and positive cash flow from operations, positioning it for investment in membership growth and Clover Assistant technology in 2025.

• Full year 2024 GAAP Net loss from continuing operations improved by $164 million year-over-year.
• Full year 2024 Adjusted EBITDA reached $70 million, an increase of $112 million year-over-year.

Sunrun achieved its third consecutive quarter of positive Cash Generation, reaching $34.2 million in Q4 2024. The company also paid down $132 million of recourse debt and saw its Net Earning Assets increase to $6.8 billion. Storage Capacity Installed grew significantly by 78% year-over-year, with attachment rates reaching 62%.

• Achieved $34.2 million in Cash Generation in Q4 2024, marking the third consecutive quarter of positive cash flow.
• Reduced recourse debt by $132 million in Q4 2024, contributing to a total of $186 million paid down since March 2024.

Alamo Group Inc. reported fourth quarter 2024 net sales of $385.3 million, a 7.7% decrease compared to the prior year. Net income for the quarter was $28.1 million, or $2.33 per diluted share. The Industrial Equipment Division saw an increase in net sales, while the Vegetation Management Division experienced a significant decline.

• Net Sales for Q4 2024 were $385.3 million, down 7.7% year-over-year.
• Industrial Equipment Division net sales increased by 11.0% to $225.5 million in Q4 2024.

LeMaitre Vascular reported a productive Q4 2024 with sales up 14%, operating income up 26%, and EPS up 30%. The company also announced an increased quarterly dividend and authorized a share repurchase program.

• Sales increased 14% to $55.7 million in Q4 2024, driven by strong organic growth.
• Operating income grew 26% to $12.9 million, with an operating margin of 23%.

Ligand Pharmaceuticals reported a strong fourth quarter and full year 2024, driven by royalty revenue growth and strategic investments. The company is reaffirming its 2025 financial guidance, expecting revenue between $180 million and $200 million and adjusted EPS between $6.00 and $6.25.

• Total revenues for Q4 2024 increased by 52% to $42.8 million compared to Q4 2023.
• Royalties for Q4 2024 were $34.8 million, a 55% increase compared to the same period in 2023, driven by Qarziba and Filspari sales.

TransMedics reported a 50% increase in total revenue to $121.6 million in Q4 2024, with net income reaching $6.9 million. For the full year, revenue grew 83% to $441.5 million, and net income was $35.5 million.

• Total revenue for Q4 2024 increased by 50% to $121.6 million compared to Q4 2023.
• Net income for Q4 2024 was $6.9 million, or $0.19 per diluted share.

Progyny, Inc. announced robust financial results for the fourth quarter of 2024, with revenue reaching $298.4 million, a 10.6% increase year-over-year. The company achieved a net income of $10.5 million and Adjusted EBITDA of $47.5 million, reflecting strong operational performance. Full year 2024 revenue increased by 7.2% to $1,167.2 million, with record Adjusted EBITDA of $198.8 million.

• Fourth quarter 2024 revenue increased by 10.6% to $298.4 million compared to $269.9 million in Q4 2023.
• Net income for Q4 2024 was $10.5 million, or $0.12 per diluted share, compared to $13.5 million, or $0.13 per diluted share in Q4 2023.

Jamf announced strong financial results for Q4 2024, with total revenue increasing by 8% year-over-year to $163.0 million and ARR growing by 10% to $646.0 million. The company also achieved a significant improvement in GAAP operating loss and a substantial increase in Non-GAAP operating income.

• Q4 total revenue grew 8% year-over-year to $163.0 million.
• ARR increased 10% year-over-year to $646.0 million as of December 31, 2024.

Cable One experienced a significant net loss in Q4 2024, primarily due to unfavorable fair value adjustments and impairment, despite an increase in cash flow from operations. Revenues saw a decline, driven by decreases in residential data and video, while business data showed growth.

• Net loss was $105.2 million in Q4 2024, a significant decrease from net income of $103.5 million in Q4 2023.
• Adjusted EBITDA decreased by 7.0% to $211.0 million in Q4 2024 compared to $226.9 million in Q4 2023.

Iovance Biotherapeutics successfully drove strong early adoption for its U.S. commercial launch of Amtagvi®, achieving the upper end of its FY24 guidance range. The company reported total product revenue of $73.7 million for Q4 2024 and $164.1 million for FY24, with significant growth in Amtagvi and Proleukin sales. Net loss for Q4 2024 was $78.6 million, a notable improvement from the previous year.

• Total product revenue for Q4 2024 was $73.7 million, driven by Amtagvi and Proleukin sales.
• Amtagvi revenue for Q4 2024 was $48.7 million, reflecting strong adoption and increasing demand.

DiamondRock Hospitality Company reported a net loss of $13.7 million in the fourth quarter of 2024, a significant decrease from a net income of $8.5 million in the same period last year, primarily due to a $32.6 million impairment loss on the Westin Washington D.C. City Center. Despite the net loss, the company saw increases in comparable revenues by 5.7% and comparable RevPAR by 5.4%.

• Net loss attributable to common stockholders was $13.7 million, or ($0.07) per diluted share, compared to net income of $8.5 million in Q4 2023.
• Comparable Revenues increased by 5.7% to $280.5 million in Q4 2024.

Rocket Companies delivered a strong performance in Q4 2024, with total revenue reaching $1.769 billion and GAAP net income of $649 million. The company also saw substantial increases in closed loan origination volume and net rate lock volume, alongside an improved gain on sale margin. Adjusted revenue and net income also showed positive trends, indicating operational efficiency and market share expansion.

• Generated total revenue, net of $1.8 billion and GAAP income of $649 million, or $0.23 earnings per diluted share.
• Rocket Mortgage generated $23.6 billion in net rate lock volume, a 47% increase compared to the same period of the prior year.

Vital Farms reported a 22.2% increase in net revenue for Q4 2024, reaching $166.0 million. Gross margin expanded to 36.1%, and net income increased by 46.8% to $10.6 million. The company's performance was driven by volume growth, price/mix benefits, and operational efficiencies.

• Net revenue increased by 22.2% to $166.0 million compared to Q4 2023.
• Gross margin expanded by 280 basis points to 36.1%.

Astrana Health, Inc. experienced substantial revenue growth in Q4 2024, with total revenue increasing by 88% year-over-year, primarily driven by a 98% increase in Care Partners revenue; however, the company reported a net loss of $7.0 million for the quarter, compared to a net income in the prior year period.

• Total revenue for Q4 2024 increased by 88% to $665.2 million, up from $353.0 million in Q4 2023.
• Care Partners revenue grew by 98% to $647.7 million in Q4 2024, compared to $326.8 million in Q4 2023.

GoodRx reported Q4 2024 revenue of $198.6 million and net income of $6.7 million. The company exited the quarter with over 7 million consumers of prescription-related offerings.

• Revenue of $198.6 million
• Net income of $6.7 million; Net income margin of 3.4%

NCR Voyix reported Q4 2024 revenue of $682 million, a net loss of $9 million, and adjusted EBITDA of $114 million. The company is executing its transformation initiatives, including the sale of Digital Banking and improvements to cost structure and the balance sheet.

• Revenue was $682 million compared to $796 million in the prior year.
• Net loss from continuing operations attributable to NCR Voyix was $9 million, compared with $272 million in the prior year.

Amphastar Pharmaceuticals reported strong financial results for the fourth quarter of 2024, with net revenues increasing to $186.5 million and GAAP net income reaching $38.0 million. The company also exceeded its long-term goal for Primatene MIST® annual sales and saw significant growth in BAQSIMI® factory sales.

• Net revenues for Q4 2024 increased to $186.5 million, up from $178.1 million in Q4 2023.
• GAAP net income for Q4 2024 was $38.0 million, or $0.74 per diluted share.

International Seaways reported a net income of $36 million for Q4 2024, with shipping revenues of $195 million. The company continued its fleet optimization program and maintained a robust balance sheet, returning capital to shareholders through dividends and share repurchases.

• Delivered strong financial results and advanced Seaways’ balanced capital allocation strategy.
• Returned over $300 million to shareholders for the second consecutive year.

Global Net Lease reported a decrease in revenue for Q4 2024 compared to Q4 2023, primarily due to significant dispositions. However, the company significantly reduced its net loss and improved its Core FFO and AFFO per share. The company also announced a binding agreement to sell its multi-tenant portfolio for approximately $1.8 billion, aiming to become a pure-play, single-tenant net lease company.

• Revenue decreased to $199.1 million in Q4 2024 from $206.7 million in Q4 2023, primarily due to $835 million in dispositions.
• Net loss attributable to common stockholders significantly improved to $17.5 million in Q4 2024 from $59.5 million in Q4 2023.

Disc Medicine reported its Q4 and full year 2024 financial results, highlighting a strong financial position with $490 million in cash, cash equivalents, and marketable securities. The company is targeting an NDA submission for bitopertin in H2 2025 and anticipates initiating a Phase 2 study for DISC-3405 in H1 2025.

• Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway.
• On track to initiate APOLLO post-marketing confirmatory trial by mid-2025.

PureCycle Technologies reported progress in Q4 2024, with improvements at the Ironton facility, the Denver, PA sorting facility coming online, and advancements in compounding. The company is engaged in over 20 trials for its PureFive™ resin and made its first major sale to Drake Extrusion Inc.

• Ironton facility saw ongoing improvements, with onstream time reaching nearly 70% in December and a max feed rate of 12,500 pounds per hour in February.
• First major sale was made to Drake Extrusion Inc., marking a substantial growth opportunity with PureFive™ resin used in continuous filament yarns.

Celldex Therapeutics reported a decrease in total revenues for Q4 2024 compared to Q4 2023, primarily due to a decrease in services performed under manufacturing and research and development agreements. The company experienced an increase in R&D and G&A expenses, leading to a higher net loss for the quarter.

• Total revenues for Q4 2024 were $1.2 million, down from $4.1 million in Q4 2023.
• Net loss for Q4 2024 was $47.1 million, or ($0.71) per share, compared to a net loss of $43.3 million, or ($0.83) per share, for Q4 2023.

Structure Therapeutics reported a net loss of $36.479 million for the fourth quarter of 2024, compared to a net loss of $24.503 million in the same period last year. The company's cash, cash equivalents, and short-term investments totaled $883.518 million at year-end 2024, indicating a strong financial position.

• Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled, with topline data anticipated by year-end 2025.
• Oral small molecule amylin receptor agonist (ACCG-2671) is undergoing IND-enabling activities, with Phase 1 initiation expected by year-end 2025.

Compass Diversified delivered strong financial results in Q4 2024, with net sales increasing by 13.8% to $620.3 million and Adjusted EBITDA growing by 29.0% to $118.2 million. This growth was primarily driven by strong performance in branded consumer businesses and improving industrial businesses.

• Net sales increased by 13.8% to $620.3 million in Q4 2024 compared to Q4 2023.
• Branded consumer net sales rose by 15.2% to $403.0 million, while industrial net sales increased by 11.4% to $217.2 million.

Goldman Sachs BDC, Inc. reported a net investment income of $0.48 per share for Q4 2024, with total investment income at $103.8 million. The company's net asset value per share decreased slightly to $13.41. The investment portfolio remained strong, primarily in senior secured debt, and the company declared a base quarterly dividend of $0.32 per share.

• Net investment income per share for Q4 2024 was $0.48, with adjusted net investment income per share at $0.47.
• Net asset value per share decreased 1.0% to $13.41 as of December 31, 2024.

National HealthCare Corporation reported a decrease in GAAP net income but an increase in adjusted net income for the quarter ended December 31, 2024. The GAAP net income attributable to NHC was $6.081 million, while the adjusted net income was $25.954 million. Diluted earnings per share were $0.39 GAAP and $1.66 non-GAAP.

• Net operating revenues and grant income for the year ended December 31, 2024 totaled $1,307,382,000, an increase of 14.5% compared to 2023.
• GAAP net income attributable to NHC for the year ended December 31, 2024 was $101,927,000, compared to $66,798,000 for 2023.

Viridian Therapeutics reported a total revenue of $72 thousand for Q4 2024, with a net loss of $79.725 million. The company ended the year with a strong cash position of $717.6 million, providing a cash runway into the second half of 2027. Key advancements were made in their TED and FcRn inhibitor portfolios, including positive phase 3 data for veligrotug.

• Positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED) were reported.
• REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing Q4W or Q8W subcutaneous (SC) VRDN-003 in active and chronic TED, are progressing as planned with topline data expected in the first half of 2026.

Novavax reported fourth-quarter revenue of $88 million and a net loss of $81 million. The company is focusing on leveraging its technology platform through partnerships and pipeline expansion, including the transition of its COVID-19 vaccine commercialization to Sanofi and advancing its COVID-19-Influenza Combination vaccine candidate.

• Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi starting with the 2025-2026 season.
• Achieved total revenue of $88 million in the fourth quarter of 2024 and $682 million for the full year.

Dyne Therapeutics reported a net loss of $89.5 million for Q4 2024. The company's cash, cash equivalents, and marketable securities totaled $642.3 million as of December 31, 2024, which, combined with proceeds from a Q1 2025 stock sale, is expected to fund operations into the second half of 2026.

• Received FDA Fast Track Designation for DYNE-101 in DM1.
• Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 planned for mid-2025 to support submission for U.S. Accelerated Approval.

Xencor's total revenue for Q4 2024 was $52.8 million, a slight increase from $51.0 million in Q4 2023. The company reported a net loss of $46.2 million for the quarter, compared to a net loss of $26.3 million in the same period last year. The diluted EPS for Q4 2024 was -$0.62.

• Total revenue for Q4 2024 increased to $52.8 million from $51.0 million in Q4 2023, primarily driven by milestone revenue from Amgen and Novartis, and non-cash royalty revenue.
• Net loss attributable to Xencor, Inc. for Q4 2024 was $45.552 million, a significant increase from $26.147 million in Q4 2023.

Alexander & Baldwin, Inc. reported net income available to A&B common shareholders of $12.4 million and Commercial Real Estate (CRE) operating profit of $22.0 million for the fourth quarter of 2024. The company saw healthy occupancy and strong leasing spreads, with a focus on continued organic and external growth opportunities.

• Net income available to A&B common shareholders was $12.4 million, or $0.17 per diluted share.
• Commercial Real Estate operating profit reached $22.0 million.

Papa John's Q4 2024 results showed a decrease in North America comparable sales, with a 4% decline driven by both company-owned and franchised restaurants. International comparable sales increased by 2%. Total revenues were $531 million, a 7% decrease compared to the previous year, and diluted earnings per share were $0.44, down from $0.79 in Q4 2023.

• North America comparable sales decreased by 4%, with Domestic Company-owned restaurants down 6% and North America franchised restaurants down 4%.
• International comparable sales increased by 2% compared to the prior year period.

HCI Group, Inc. reported a pre-tax income of $5.9 million and net income of $4.1 million for the fourth quarter of 2024. Diluted earnings per share were $0.23. Consolidated gross premiums earned increased by 38.0% to $297.5 million, primarily due to policy assumptions from Citizens Property Insurance Corporation. The company also saw an increase in net investment income and a reversal of previously accrued benefits related to retrospective reinsurance provisions.

• Pre-tax income for Q4 2024 was $5.9 million, with diluted EPS of $0.23.
• Consolidated gross premiums earned increased by 38.0% to $297.5 million in Q4 2024, driven by Citizens Property Insurance Corporation policy assumptions.

Tutor Perini reported a net loss for Q4 2024, but highlighted record operating cash flow and backlog growth. The company reduced its debt significantly and anticipates double-digit revenue growth and improved profitability in 2025.

• Generated very strong operating cash flow of $329.6 million in Q4 2024.
• Reduced total debt by $477 million, or 52%, from the end of 2023 through February 27, 2025.

Fox Factory Holding Corp. delivered on its financial commitments for Q4 2024, with net sales of $352.8 million, an increase of 6.1% year-over-year. The company achieved a gross margin of 28.9% and adjusted gross margin of 29.2%. Earnings per diluted share were breakeven, while adjusted earnings per diluted share were $0.31. Working capital improvements led to a $63 million debt paydown.

• Net sales for the fourth quarter of fiscal 2024 were $353 million, up $20 million over the prior year.
• Gross margin achieved 28.9%, an increase of 120 basis points over the prior year.

American Woodmark Corporation reported a decrease in net sales by 5.8% to $397.6 million and a decrease in net income to $16.6 million for the third quarter of fiscal year 2025. The results were impacted by softer demand in the remodel market and a decline in new construction single family activity.

• Net sales reached $397.6 million.
• Net income was $16.6 million, representing 4.2% of net sales.

Spyre Therapeutics reported no revenue for Q4 2024, with a net loss of $56.3 million. The company ended the quarter with $603.1 million in cash, cash equivalents, and marketable securities, extending its cash runway into the second half of 2028. Key developments included positive interim Phase 1 data for SPY001 and expansion of SPY002 into rheumatoid arthritis.

• Reported positive interim pharmacokinetic and safety data from the Phase 1 trial of SPY001 in November 2024.
• Strengthened the balance sheet with a $230 million public offering, extending cash runway into the second half of 2028.

Pacira BioSciences, Inc. reported a 3% increase in total revenues for the fourth quarter of 2024, reaching $187.3 million, compared to $181.2 million in the same period last year. The company's GAAP net income for the quarter was $16.0 million, or $0.35 per basic share. Full-year revenues for 2024 were $701.0 million, a 4% increase from 2023.

• Fourth quarter revenues increased by 3% to $187.3 million.
• GAAP net income for Q4 2024 was $16.0 million, or $0.35 per basic share.

Aurinia Pharmaceuticals reported strong financial results for Q4 2024, with a significant increase in total revenue and a return to net income profitability. The company's key product, LUPKYNIS, drove sales growth, and the company is progressing with its pipeline development.

• Total revenue for Q4 2024 was $59.9 million, a 33% increase year-over-year.
• Net product sales of LUPKYNIS were $57.6 million, a 36% increase year-over-year.

Arlo Technologies, Inc. delivered strong Q4 2024 results, with annual recurring revenue (ARR) growing 22.5% year over year to $257.3 million and service revenue increasing 14.7% to $64.1 million. The company achieved record GAAP and non-GAAP service gross margins of 81.2% and 81.7% respectively, demonstrating improved profitability. Cumulative paid accounts grew significantly by 63.5% year over year, reaching 4.6 million.

• Annual recurring revenue (ARR) reached $257.3 million, marking a 22.5% year-over-year increase.
• Service revenue for Q4 2024 was $64.1 million, up 14.7% from the previous year, accounting for 53% of total revenues.

Cars.com reported a slight increase in Q4 revenue to $180.4 million, with a significant 15% year-over-year growth in OEM and National revenue. Adjusted EBITDA margin reached nearly 31%. The company also announced a $250 million share repurchase authorization.

• OEM and National revenue increased by 15% year-over-year.
• Adjusted EBITDA margin was nearly 31%.

Bain Capital Specialty Finance, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2024, which will be reported after market close on Thursday, February 27, 2025. Management will host a conference call on Friday, February 28, 2025, to discuss the results.

• Bain Capital Specialty Finance, Inc. (BCSF) will report Q4 and FY 2024 financial results on February 27, 2025.
• A conference call to discuss the results will be held on February 28, 2025, at 8:00 a.m. Eastern Time.

Ameresco concluded 2024 with a strong fourth quarter, achieving a 20.7% increase in total revenue to $532.7 million. The company saw record contract conversions of over $1 billion, leading to a 92% year-over-year increase in contracted project backlog. Full year revenue grew by 29%, and a record 241 MWe of energy assets were placed in operation.

• Total revenue for Q4 2024 increased by 20.7% to $532.7 million, with full year revenue growth of 29%.
• Contracted project backlog reached over $2.5 billion at year-end, approximately twice 2023 levels, driven by record Q4 contract conversions of $1.1 billion.

Ellington Financial reported net income attributable to common stockholders of $22.4 million, or $0.25 per common share, for the fourth quarter of 2024. Adjusted distributable earnings were $40.6 million, or $0.45 per common share, covering the $0.39 per share dividends for the quarter. The company saw strong performance from its loan originator affiliates and securitization-related gains.

• Net income attributable to common stockholders was $22.4 million, or $0.25 per common share.
• Adjusted Distributable Earnings were $40.6 million, or $0.45 per common share, covering the quarterly dividends.

Rocket Pharmaceuticals reported a net loss of $60.3 million for Q4 2024, with total operating expenses of $62.7 million. The company's cash, cash equivalents, and investments stood at $372.3 million, providing an operational runway into Q3 2026.

• Dosing is ongoing in the Phase 2 pivotal study of RP-A501 for Danon disease, with an update expected in the first half of 2025.
• Enrollment was completed in the low-dose cohort of the Phase 1 study of RP-A601 for PKP2-ACM, with initial data expected in the first half of 2025.

Collegium Pharmaceutical, Inc. achieved record financial results in Q4 2024, with net revenue of $181.9 million and adjusted EBITDA of $107.7 million. The company also reported GAAP net income of $12.5 million and repurchased $60.0 million in shares during 2024.

• Generated record quarterly net revenue of $181.9 million, a 22% increase year-over-year.
• Achieved quarterly GAAP net income of $12.5 million and adjusted EBITDA of $107.7 million.

Intellia Therapeutics reported its Q4 and full-year 2024 financial results, highlighting the dosing of the first patient in the global Phase 3 HAELO study for NTLA-2002 and the continued progress of the Phase 3 MAGNITUDE trial for nexiguran ziclumeran. The company ended the year with approximately $862 million in cash, cash equivalents, and marketable securities.

• Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE).
• Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics License Application in the second half of 2026 to support plans for U.S. launch in 2027.

Array Technologies reported strong fourth quarter and full year 2024 results, exceeding the mid-point of their fourth quarter revenue guidance and achieving a record gross margin for the full year, driven by robust profitability and healthy cash flow.

• Revenue for Q4 2024 was $275.2 million, exceeding the mid-point of guidance.
• Gross Margin for Q4 2024 was 28.5%, with Adjusted Gross Margin at 29.8%.

89bio, a clinical-stage biopharmaceutical company, reported a net loss of $118.4 million for the fourth quarter of 2024, an increase from the $40.2 million net loss in the same period last year. This was primarily driven by higher research and development expenses due to contract manufacturing and the advancement of Phase 3 programs, as well as increased general and administrative expenses.

• Net loss for Q4 2024 was $118.4 million, significantly higher than $40.2 million in Q4 2023.
• Diluted EPS for Q4 2024 was -$1.02, compared to -$0.50 in Q4 2023.

TriMas reported an 8.8% increase in net sales for Q4 2024, driven by growth in its Packaging and Aerospace segments. The company's adjusted diluted earnings per share increased by 13.2%.

• Achieved quarterly sales growth of 22.3% within its Aerospace group, contributing to record annual group sales of $294.2 million.
• Reported sales growth within its Packaging group of 8.4% for the quarter.

Paramount Group, Inc. reported a net loss attributable to common stockholders of $38.6 million for the fourth quarter of 2024, a significant improvement from the $205.6 million loss in the same period last year. Core FFO attributable to common stockholders was $41.2 million, or $0.19 per diluted share. Same Store NOI decreased slightly by 0.4%, while leased occupancy increased by 10 basis points to 84.8%.

• Net loss attributable to common stockholders improved significantly to $38.6 million in Q4 2024 from $205.6 million in Q4 2023, primarily due to lower non-cash real estate impairment losses.
• Core Funds from Operations (Core FFO) attributable to common stockholders was $41.2 million, or $0.19 per diluted share, for Q4 2024.

Ducommun Incorporated reported solid fourth-quarter results with a 2.6% increase in net revenue, a gross margin increase of 180 bps, and a 33% increase in net income year-over-year. The company achieved record full-year revenue and gross margins, driven by growth in the military and space business and strategic initiatives under VISION 2027.

• Net revenue increased by 2.6% to $197.3 million compared to Q4 2023.
• Gross margin improved by 180 bps year-over-year to 23.5%.

OPKO Health, Inc. announced its fourth quarter 2024 results, reporting total revenues of $183.6 million, a slight increase from the previous year. The company achieved a net income of $14.0 million, a substantial improvement from a net loss of $66.5 million in the prior year, primarily due to a $54.1 million gain from the sale of GeneDx shares and $21.4 million in non-cash other income.

• Net income significantly improved to $14.0 million in Q4 2024 from a $66.5 million loss in Q4 2023, largely due to a realized gain on asset sales.
• Operating loss decreased to $33.1 million in Q4 2024 from $69.1 million in Q4 2023, reflecting better operational efficiency.

AbCellera reported Q4 2024 revenue of $5.1 million and a net loss of $34.2 million. The company continues to advance its pipeline and invest in its capabilities.

• Revenue for Q4 2024 was $5.1 million, primarily from research fees.
• Operating expenses for Q4 2024 totaled $77.8 million, including investments in co-development and internal programs.

Opendoor Technologies Inc. announced its Q4 2024 financial results, with revenue of $1.1 billion and a net loss of $(113) million. The company demonstrated strong execution in 2024, achieving a full-year gross margin of 8.4% and significantly reducing Adjusted Net Losses.

• Revenue for Q4 2024 was $1.1 billion, up 25% compared to Q4 2023.
• Net loss for Q4 2024 was $(113) million, compared to $(91) million in Q4 2023.

Blend Labs, Inc. reported a strong fourth quarter in 2024, with total revenue increasing 15% year-over-year to $41.4 million. The company achieved non-GAAP income from operations of $5.2 million, significantly surpassing guidance, and saw a 48% annual revenue growth in its Consumer Banking business.

• Total revenue for Q4 2024 was $41.4 million, a 15% increase year-over-year.
• Non-GAAP income from operations reached $5.2 million, exceeding guidance.

FIGS, Inc. announced its fourth quarter and full year 2024 financial results, with Q4 net revenues increasing by 4.8% year over year to $151.8 million, primarily driven by increased orders from existing customers. Net income for Q4 was $1.9 million, or $0.01 diluted earnings per share. For the full year 2024, net revenues grew by 1.8% to $555.6 million, and net income was $2.7 million, or $0.02 diluted earnings per share.

• Q4 2024 net revenues increased by 4.8% year over year to $151.8 million, exceeding expectations.
• Full year 2024 net revenues grew by 1.8% to $555.6 million.

The Pennant Group, Inc. announced robust operating results for the fourth quarter and fiscal year ended December 31, 2024. Total revenue for the fourth quarter increased by 29.4% to $188.9 million, and diluted GAAP earnings per share were $0.16. Adjusted diluted earnings per share for the quarter stood at $0.24, reflecting strong operational performance and strategic expansion.

• Total revenue for the fourth quarter increased by 29.4% year-over-year to $188.9 million.
• GAAP diluted earnings per share for the fourth quarter were $0.16, with adjusted diluted earnings per share at $0.24.

Nextdoor concluded 2024 with a strong Q4, seeing revenue increase by 17% year-over-year to $65 million. The company achieved positive adjusted EBITDA of $3 million and generated $11 million in operating cash flow. Weekly Active Users (WAU) grew 10% year-over-year to 45.9 million, and the company maintained a disciplined balance between strategic investments and cost controls.

• Revenue increased 17% year-over-year to $65 million in Q4 2024, driven by performance-optimized campaigns for self-serve advertisers.
• Adjusted EBITDA turned positive at $3 million (5% margin) in Q4 2024, representing a 30 percentage point improvement year-over-year.

Accel Entertainment concluded 2024 with strong performance, achieving record revenues for both Q4 and the full year, driven by an increase in locations and gaming terminals. The company also expanded into new markets through strategic acquisitions and replenished its share repurchase program.

• Record revenues of $317.5 million for Q4 2024, an increase of 6.9% compared to Q4 2023.
• Ended Q4 2024 with 4,117 locations, a 3.9% increase compared to Q4 2023.

Golden Entertainment reported a sequential improvement in fourth-quarter performance and anticipates continued business improvement in 2025. The company repurchased 1.1 million shares of common stock and paid quarterly cash dividends.

• Fourth quarter 2024 revenues were $164.2 million, a decrease from $230.7 million in Q4 2023, primarily due to the exclusion of distributed gaming operations in Nevada that were sold.
• Net income for Q4 2024 was $3.0 million, or $0.10 per fully diluted share, compared to a net loss of $9.4 million in Q4 2023.

Ecovyst reported Q4 2024 sales of $182.0 million, a 5% increase compared to Q4 2023. The company experienced a net loss of $30.5 million, but adjusted net income was $33.0 million. Adjusted EBITDA increased by 8.7% to $75.9 million, with a margin of 35.3%. The Ecoservices segment saw increased sales volume and positive pricing, while the Advanced Materials & Catalysts segment experienced higher sales in advanced silicas but lower sales in the Zeolyst Joint Venture.

• Sales increased by 5% to $182.0 million compared to the fourth quarter of 2023.
• Net loss was $30.5 million, with a diluted net loss per share of $0.26.

uniQure reported a net loss of $239.6 million for the year ended December 31, 2024. The company is focusing on advancing its gene therapy pipeline, particularly AMT-130 for Huntington's disease, and has streamlined operations to extend its cash runway into the second half of 2027.

• Aligned with the FDA on key elements for Accelerated Approval pathway of AMT-130 in Huntington’s disease and initiated preparations for BLA submission.
• Completed patient enrollment in the third cohort of the Phase I/II study of AMT-130.

SITE Centers reported a net loss attributable to common shareholders of $13.2 million, or $0.25 per diluted share, for the fourth quarter of 2024. The company redeemed all outstanding 6.375% Class A Cumulative Redeemable Preferred Shares and reported a leased rate of 91.1% and a commenced rate of 90.6% at December 31, 2024.

• Redeemed all outstanding 6.375% Class A Cumulative Redeemable Preferred Shares and the associated depositary shares at par.
• A charge of $6.2 million was recorded for the write off of the remaining original issuance costs.

FTAI Infrastructure Inc. reported a net loss attributable to stockholders of $137.2 million for Q4 2024, with basic and diluted loss per share of $1.24. Adjusted EBITDA was $29.173 million, and Adjusted EBITDA from Four Core Segments was $39.777 million. The company also declared a cash dividend of $0.03 per share.

• Net loss attributable to stockholders for Q4 2024 was $137.236 million.
• Basic and diluted loss per share for Q4 2024 was $1.24.

Stagwell reported Q4 2024 results with a 20% YoY revenue increase, driven by a 22% growth in Digital Transformation. Net revenue grew by 14%, with organic net revenue up 10%. The company achieved a net income of $3 million and an adjusted EBITDA of $123 million, representing a 20% margin on net revenue. EPS was $0.03, with adjusted EPS at $0.24.

• Q4 revenue increased by 20% YoY, reaching $789 million.
• Q4 net revenue grew by 14% YoY, with organic net revenue up 10%.

Castle Biosciences delivered an outstanding fourth quarter, achieving 31% revenue growth and a significant increase in net income compared to the same period in 2023. The company also reported a substantial increase in total test reports delivered, particularly in TissueCypher Barrett's Esophagus tests.

• Revenues increased by 31% to $86.3 million in Q4 2024 compared to Q4 2023.
• Net income for Q4 2024 was $9.6 million, a significant improvement from a net loss of $2.6 million in Q4 2023.

Cytek Biosciences reported a Q4 2024 revenue of $57.5 million, a 1.3% decrease compared to Q4 2023. Gross profit increased by 1.8% to $33.7 million, and net income was $9.6 million, including a non-recurring benefit. Adjusted EBITDA was $12.5 million.

• Total revenue for the fourth quarter of 2024 was $57.5 million, a 1.3% decrease from the fourth quarter of 2023.
• Gross profit for the fourth quarter of 2024 was $33.7 million, an increase of 1.8% compared to the fourth quarter of 2023.

PubMatic delivered a strong performance in Q4 2024, with revenue increasing by 1% year-over-year to $85.5 million. The company reported a net income of $13.9 million and an adjusted EBITDA of $37.6 million, demonstrating continued profitability and operational efficiency. CTV revenue more than doubled year-over-year, representing 20% of total revenue, highlighting a significant shift in ad buying towards high-engagement channels.

• Q4 2024 revenue reached $85.5 million, a 1% increase over the same period in 2023.
• CTV revenue in Q4 more than doubled year-over-year, accounting for 20% of total revenue.

Cronos Group reported a 27% increase in net revenue for Q4 2024, reaching $30.3 million, driven by strong performance in the Canadian and Israeli markets. The company's strategic investments and brand leadership have positioned it for continued growth in the global cannabis industry.

• Net revenue increased by 27% year-over-year to $30.3 million.
• Spinach® maintained its position as the number one flower brand in Canada.

Thryv Holdings, Inc. reported a strong fourth quarter with a 41% year-over-year increase in Total SaaS revenue. The company achieved a SaaS Adjusted EBITDA margin of 17% and saw a 73% increase in total SaaS subscribers with the addition of Keap's SaaS clients.

• Total SaaS revenue increased by 41% year-over-year.
• Thryv SaaS revenue, excluding Keap's revenue, increased by 23% year-over-year.

OneSpan concluded the year with a strong fourth quarter, marked by significant growth in subscription revenue and improved profitability, alongside robust cash generation. The company's strategic investments and operational focus have positioned it for sustained revenue growth and profitability.

• Fourth quarter operating income significantly increased to $11.8 million, up from $1.8 million in the same period last year.
• Subscription revenue for the fourth quarter grew by 32% year-over-year, reaching $36.1 million.

Standard Motor Products reported an 18.1% increase in fourth-quarter net sales, reaching $343 million, and a 7.8% increase for the full year. Adjusted diluted earnings per share increased by 27% for the quarter and 8.6% for the year. The acquisition of Nissens Automotive contributed $35.7 million in sales during the quarter.

• Fourth quarter net sales increased by 18.1%, and 5.8% excluding Nissens.
• Nissens acquisition, closed in November, contributed $35.7 million to sales in the quarter.

Lindblad Expeditions Holdings, Inc. reported a 19% increase in fourth-quarter tour revenues to $148.6 million compared to the same period in 2023, driven by growth in both Lindblad and Land Experiences segments. The net loss available to stockholders improved by $2.3 million, and Adjusted EBITDA increased by $9.6 million.

• Fourth quarter tour revenues increased by 19% to $148.6 million.
• Lindblad segment tour revenues increased by 6% due to higher net yield per available guest night and increased occupancy.

Verve Therapeutics reported progress in its pipeline development, including the Heart-2 Phase 1b clinical trial of VERVE-102 and the Pulse-1 Phase 1b clinical trial of VERVE-201. The company's cash, cash equivalents, and marketable securities totaled $524.3 million, expected to fund operations into mid-2027. Frederick T. Fiedorek, M.D., will retire from his position as Chief Medical Officer, effective February 28, 2025.

• Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 is expected in the second quarter of 2025.
• VERVE-102 has been well-tolerated in the Heart-2 trial, with no treatment-related serious adverse events observed.

Metallus reported fourth-quarter 2024 net sales of $240.5 million and a net loss of $21.4 million, or $0.50 per diluted share. On an adjusted basis, the net loss was $3.3 million, or $0.08 per diluted share, with adjusted EBITDA of $8.3 million. This represents a sequential improvement in net sales and adjusted EBITDA compared to the third quarter of 2024, but a decline from the fourth quarter of 2023.

• Net sales for Q4 2024 were $240.5 million, a 6% increase sequentially but a 27% decrease compared to Q4 2023.
• The company reported a net loss of $21.4 million for Q4 2024, with an adjusted EBITDA of $8.3 million.

Koppers reported a net loss of $10.2 million for Q4 2024, compared to a net income of $12.9 million in Q4 2023. However, adjusted EPS increased to $0.77 from $0.67 in the prior year quarter. Sales decreased by 7.1% to $477.0 million, primarily due to lower volumes and decreased prices across most products.

• Fourth-quarter sales decreased to $477.0 million from $513.2 million in the prior year quarter.
• Net loss attributable to Koppers was $10.2 million, or $0.50 per diluted share, compared to net income of $12.9 million, or $0.59 per diluted share in the prior year quarter.

Marcus Corporation reported a 16.6% increase in total revenues to $188.3 million for Q4 2024, driven by a stronger film slate at Marcus Theatres and continued strong performance at Marcus Hotels & Resorts. Net earnings were $1.0 million, or $0.03 per diluted common share, compared to a net loss of $1.4 million, or $0.05 per diluted common share, for the same period in fiscal 2023.

• Total revenues increased by 16.6% compared to the prior year quarter, reaching $188.3 million.
• Net earnings improved to $1.0 million, or $0.03 per diluted common share.

Ironwood Pharmaceuticals reported its fourth quarter and full year 2024 results, highlighting progress with apraglutide and continued LINZESS demand growth. The company is preparing for the potential launch of apraglutide and streamlining operations for long-term value creation.

• Reported positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time.
• Initiated rolling NDA submission for apraglutide, on track to be completed in Q3 2025.

American Coastal Insurance Corporation remained profitable in Q4 2024 with a combined ratio of 91.9%, despite the impact of Hurricane Milton. Gross written premium increased by 9.7% quarter-over-quarter, and the company launched its apartment program.

• Gross premiums written increased by 9.7% to $140.7 million in Q4 2024.
• Consolidated net income for Q4 2024 was $4.9 million, a decrease from $14.3 million in Q4 2023.

Treace Medical Concepts reported a 10% increase in revenue for Q4 2024, reaching $68.7 million, and significantly improved its net loss and Adjusted EBITDA compared to the same period in 2023, driven by product mix shift, adoption of newer technologies, and increased bunion procedure kits sold.

• Fourth quarter 2024 revenue increased 10% to $68.7 million compared to the same period in 2023.
• Net loss for Q4 2024 improved to ($0.5) million from ($6.3) million in Q4 2023.

Cullinan Therapeutics reported its Q4 and full year 2024 financial results, highlighting key updates for CLN-978 and zipalertinib. The pivotal Phase 2b study for zipalertinib met its primary endpoint, with NDA submission planned for H2 2025. The company's cash and investments totaled $606.9 million, providing runway into 2028.

• CLN-978 remains the only development-stage CD19 T cell engager in an autoimmune disease clinical trial in the U.S.
• Zipalertinib pivotal Phase 2b study met the primary endpoint.

nLIGHT, Inc. reported a challenging fourth quarter and full year 2024, with revenues decreasing by 8.7% to $47.4 million for Q4 2024 compared to the previous year. The company experienced a significant GAAP net loss of $25.0 million for the quarter, an 88.6% increase from Q4 2023, largely impacted by non-routine charges of approximately $6.0 million related to inventory reserves.

• Fourth quarter 2024 revenue decreased by 8.7% year-over-year to $47.4 million.
• GAAP net loss for Q4 2024 was $25.0 million, an 88.6% increase from Q4 2023.

Global Medical REIT experienced a 6.1% year-over-year increase in rental revenue for Q4 2024, reaching $35.0 million, primarily driven by recent acquisitions. Despite this, net income attributable to common stockholders was $1.4 million, or $0.02 per diluted share, impacted by one-time severance costs and an impairment charge. The company also announced a joint venture with Heitman and provided 2025 AFFO guidance.

• Rental revenue for the fourth quarter of 2024 increased by 6.1% year-over-year to $35.0 million, driven by acquisitions.
• Net income attributable to common stockholders for Q4 2024 was $1.4 million ($0.02 per diluted share), compared to a net loss of $0.8 million ($0.01 per diluted share) in the prior year period.

Definitive Healthcare reported Q4 2024 revenue of $62.3 million, a 6% decrease from Q4 2023. The company experienced a net loss of $(84.7) million, significantly impacted by goodwill impairment charges of $97.1 million. Despite the net loss, adjusted net income increased to $12.6 million and adjusted EBITDA was $17.5 million, representing 28% of revenue.

• Q4 2024 revenue was $62.3 million, a 6% decrease year-over-year.
• Net loss for Q4 2024 was $(84.7) million, primarily due to $97.1 million in goodwill impairment charges.

Altimmune reported a net loss of $23.2 million for the fourth quarter of 2024, with cash, cash equivalents, and short-term investments totaling $131.9 million as of December 31, 2024. The company is advancing pemvidutide in multiple indications and expects to report top-line data from the Phase 2b IMPACT trial in Q2 2025.

• IMPACT Phase 2b trial of pemvidutide in MASH is on track to report top-line data in Q2 2025.
• IND applications for pemvidutide in two additional indications have been cleared by the FDA, with Phase 2 trials expected to commence mid-2025.

Entrada Therapeutics reported a net income of $1.1 million for Q4 2024, with collaboration revenue reaching $37.4 million. The company's cash, cash equivalents, and marketable securities totaled $420 million, expected to fund operations into Q2 2027.

• Received FDA authorization to initiate ELEVATE-44-102 in the U.S.
• Received MHRA authorization to initiate ELEVATE-44-201 in the U.K.

DocGo's fourth quarter 2024 revenue decreased to $120.8 million from $199.2 million in the prior year, mainly due to the wind-down of migrant-related programs. The company reported a net loss of $7.6 million for the quarter, compared to a net income of $8.0 million in Q4 2023. Full-year 2024 revenue was $616.6 million, with a GAAP gross margin of 32.1%.

• Total revenue for Q4 2024 was $120.8 million, a significant decrease from $199.2 million in Q4 2023, primarily due to the wind-down of migrant-related programs.
• The company reported a net loss of $7.6 million in Q4 2024, contrasting with a net income of $8.0 million in Q4 2023.

Organogenesis Holdings Inc. announced a robust fourth quarter for 2024, with net revenue reaching $126.7 million, a 27% increase from Q4 2023. The company also reported a net income of $7.7 million, a substantial improvement from a net loss in the prior year, and Adjusted EBITDA of $18.2 million, marking a 143% increase.

• Net revenue for Q4 2024 increased by 27% to $126.7 million, driven by growth in both Advanced Wound Care and Surgical & Sports Medicine products.
• The company achieved a net income of $7.7 million in Q4 2024, a significant turnaround from a net loss of $0.6 million in Q4 2023.

Personalis, Inc. reported a fourth quarter 2024 revenue of $16.8 million, a 15% decrease from the prior year, primarily due to expected declines from Natera and VA MVP. Despite the revenue decrease, the company significantly reduced its net loss to $16.4 million from $26.6 million in the same period last year. The company also highlighted a strategic investment of $50 million from Merck and an expanded partnership with Tempus AI.

• Fourth quarter 2024 revenue was $16.8 million, a 15% decrease year-over-year.
• Net loss for Q4 2024 improved to $16.4 million, compared to $26.6 million in Q4 2023.

Codexis reported a 17% increase in total revenues for Q4 2024 to $21.5 million, excluding PAXLOVID™ enzyme sales, compared to $18.4 million in Q4 2023. The company's net loss for Q4 2024 was $10.4 million, or $0.13 per share. For the full fiscal year 2024, total revenues were $59.3 million, a 4% decrease from $62.0 million in FY 2023, excluding PAXLOVID™ enzyme sales.

• Total revenues for Q4 2024 increased by 17% to $21.5 million, excluding PAXLOVID™ enzyme sales.
• Net loss for Q4 2024 was $10.4 million, or $0.13 per share.

Gray Media reported a strong fourth quarter with a 21% increase in total revenue, driven by significant growth in political advertising revenue. The company also reduced its outstanding debt and improved its leverage ratio. Net income attributable to common stockholders was $156 million, a significant turnaround from the previous year's net loss.

• Total revenue increased by 21% to $1.0 billion compared to Q4 2023.
• Political advertising revenue surged by 658% to $250 million due to the on-year of the two-year political advertising cycle.

Eventbrite's Q4 2024 performance showed revenue at $76.5 million, a 13% year-over-year decrease, but within the upper end of their guidance. The company achieved an Adjusted EBITDA of $6.5 million, representing an 8.5% margin. Net loss for the quarter was $8.4 million. Key operating metrics indicated a return to growth in total and free ticket volumes, while paid tickets, paid transacting creators, and paid events showed improved year-over-year comparisons from the previous quarter.

• Net Revenue of $76.5 million was at the upper end of the company's outlook range.
• Adjusted EBITDA of $6.5 million exceeded the fiscal year 2024 margin target.

iHeartMedia, Inc. reported a strong fourth quarter in 2024 with consolidated revenue up 4.8% and consolidated Adjusted EBITDA increasing by 18.2%. The company also successfully completed a debt exchange transaction, reducing net debt to its lowest historical level and extending maturities.

• Consolidated revenue for Q4 2024 increased by 4.8% to $1,118 million, driven by political and digital revenue growth.
• Consolidated Adjusted EBITDA for Q4 2024 rose by 18.2% to $246 million, marking the highest percentage increase in almost three years.

Civeo reported Q4 2024 revenues of $151.0 million with a net loss of $15.1 million. The Australian segment experienced revenue growth of 23%. The Canadian segment faced headwinds, with revenues decreasing by 44%.

• Fourth quarter revenues were reported at $151.0 million.
• The net loss for the fourth quarter was $15.1 million.

Grupo Fleury achieved a gross revenue of R$ 2.0 billion in 4Q24, an 8.7% increase over 4Q23, with EBITDA reaching R$ 405.5 million (22.0% margin) and Net Income of R$ 84.0 million. The company demonstrated consistent performance across its segments, with significant growth in mobile services and B2B diagnostic medicine, while maintaining a solid financial structure with reduced leverage.

• Gross Revenue reached R$ 1,994.3 million in 4Q24, an 8.7% increase compared to 4Q23.
• EBITDA for 4Q24 was R$ 405.5 million, with a margin of 22.0%, showing a 7.9% growth over 4Q23.

Expensify delivered a strong Q4 2024, with revenue increasing 5% quarter-over-quarter, significant improvements in net loss and Adjusted EBITDA, and positive cash flow. The company also successfully paid off $22.7 million in debt, becoming debt-free.

• Q4 Revenue increased 5% quarter-over-quarter, reaching $37.0 million.
• The company generated $23.9 million in Operating Cash Flow and Free Cash Flow for fiscal year 2024, exceeding forecasts.

Outbrain's Q4 2024 results showed a revenue of $234.6 million, a gross profit of $56.1 million, and a net loss of $0.2 million. The company's Ex-TAC gross profit increased by 7% to $68.3 million, and Adjusted EBITDA rose to $17.0 million. Strong cash flow was generated, with free cash flow reaching $37.6 million.

• Outbrain achieved accelerated growth and profitability.
• The company met Q4 guidance on Ex TAC gross profit and Adjusted EBITDA.

Heron Therapeutics reported a successful Q4 2024, achieving GAAP net income of $3.6 million. Full-year 2024 net revenue reached $144.2 million, a 14% increase year-over-year. The company is focused on expanding ZYNRELEF's market reach and indications, supported by strategic partnerships and regulatory approvals.

• Achieved Q4 2024 GAAP Net Income of $3.6 million.
• Full-year 2024 Net Revenue reached $144.2 million, up 14% year-over-year.

Solid Power delivered $20.1 million in revenue during 2024, an increase of $2.7 million compared to 2023, primarily driven by performance on SK On Agreements. The company reported a net loss of $96.5 million for the full year 2024.

• Successfully progressed strategic partnerships and completed 2024 milestones with SK On, BMW, and Ford.
• Continued repeated electrolyte sampling to potential customers, driving improvements to formulations and production processes.

Aclaris Therapeutics reported Q4 2024 financial results, featuring a revenue of $9.2 million and a net loss of $96.6 million. The company highlighted its cash runway extending into 2028 and progress in its clinical development programs.

• Aclaris reported Q4 2024 revenue of $9.2 million, compared to $17.6 million in Q4 2023.
• The company experienced a net loss of $96.6 million for Q4 2024, compared to a net loss of $1.5 million for Q4 2023.

Rimini Street announced a revenue of $114.2 million for the fourth quarter of 2024, an increase of 1.9% year-over-year. The company reported a net income of $6.7 million and basic and diluted earnings per share of $0.07. Gross margin improved to 63.7% from 61.0% in the prior year.

• Revenue for Q4 2024 increased by 1.9% year-over-year to $114.2 million.
• Gross margin improved to 63.7% in Q4 2024, up from 61.0% in the same period last year.

C4 Therapeutics reported increased revenue for Q4 2024, primarily driven by new collaborations. The company's net loss remained relatively flat compared to the prior year, and its cash position is expected to provide a runway into 2027.

• Revenue from collaboration agreements increased to $5.177 million in Q4 2024 from $3.261 million in Q4 2023.
• Net loss for Q4 2024 was $34.573 million, a slight improvement from $34.754 million in Q4 2023.

Silence Therapeutics reported its full year 2024 financial results. The company ended the year with over $147 million in cash, cash equivalents and short-term investments and is extending its projected cash runway into 2027 by prioritizing divesiran in PV and programs in rare conditions.

• Cash, cash equivalents, and short-term investments were $147.3 million at the end of December 2024.
• Collaboration revenue was $43.1 million for the year ended December 31, 2024.

Compass Pathways reported a net loss of $43.3 million for the quarter ended December 31, 2024. The company's cash and cash equivalents were $165.1 million as of December 31, 2024. Phase 3 COMP005 trial in participants with treatment resistant depression (TRD) 6-week top-line data on track for second quarter 2025.

• Phase 3 COMP005 trial in participants with treatment resistant depression (TRD) 6-week top-line data on track for second quarter 2025
• Phase 3 COMP006 in TRD is on track for 26-week data in second half of 2026

Cardiff Oncology announced positive initial data from its ongoing first-line RAS-mutated mCRC clinical trial (CRDF-004), with a 64% objective response rate in the 30mg onvansertib dose arm. The company also raised $40 million in an oversubscribed offering, strengthening its cash position to $91.7 million, projected to fund operations into Q1 2027.

• Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut mCRC clinical trial (CRDF-004).
• Priced oversubscribed $40 million underwritten registered direct offering with participation from new and existing healthcare dedicated investors.

Nerdy Inc. announced strong fourth quarter 2024 financial results, with revenue of $48.0 million and a non-GAAP adjusted EBITDA loss of $5.5 million, both surpassing the high end of their guidance ranges. The company made significant progress in unifying platforms and enhancing marketplace technology, driven by AI innovation, and ended the year with a strong cash position.

• Fourth quarter revenue reached $48.0 million, exceeding the guidance range of $44 to $47 million.
• Non-GAAP adjusted EBITDA loss was $5.5 million, better than the guidance of negative $7.0 million to negative $10.0 million.

TTEC Holdings, Inc. announced its fourth quarter and full year 2024 financial results, reporting a Q4 revenue of $567.4 million, a 9.4% decrease year-over-year, and a net income of $4.6 million. For the full year, revenue was $2.208 billion, down 10.4%, with a net loss of $310.6 million. Despite the challenging year, the company highlighted progress in its diversification strategy, digital CX value proposition, and profitability improvement initiatives, providing an optimistic outlook for 2025.

• Fourth quarter 2024 GAAP revenue was $567.4 million, a 9.4 percent decrease compared to the prior year.
• Net income for Q4 2024 was $4.6 million, or 0.8 percent of revenue, while Adjusted EBITDA was $50.9 million, or 9.0 percent of revenue.

GoHealth, Inc. reported a strong fourth quarter with net revenues of $389.1 million, a 41% increase compared to the prior year period. Net income was $58.0 million, a substantial improvement compared to the prior year period, and Adjusted EBITDA surged to $117.8 million, a significant 107% increase compared to the prior year period.

• Achieved net revenues of $389.1 million, a substantial 41% increase compared to the prior year period.
• Submissions grew to 481,445, representing a 67% increase compared to the prior year period.

QVC Group reported a 6% decrease in revenue and an operating loss of $1.3 billion for the fourth quarter of 2024. The company faced challenges including heightened competition, a conservative consumer environment, and sales deleverage. However, QVC Group is implementing a new three-year strategy focused on live social shopping and is actively managing its balance sheet.

• QVC Group revenue decreased 6% in Q4 2024.
• The company generated an operating loss of $1.3 billion in Q4 2024.

Puma Biotechnology announced strong financial results for the fourth quarter of 2024, with net income increasing to $19.3 million and product revenue reaching $54.4 million. The company also reported positive net income for the third consecutive year, driven by commercial performance and strategic initiatives.

• Product revenue, net, for Q4 2024 was $54.4 million, an increase from $53.2 million in Q4 2023.
• Net income for Q4 2024 was $19.3 million, or $0.39 per basic and diluted share, up from $12.3 million in Q4 2023.

Ventyx Biosciences reported a net loss of $29.4 million for Q4 2024, an improvement from the $46.8 million net loss in Q4 2023. The company's cash, cash equivalents, and marketable securities stood at $252.9 million as of December 31, 2024, which is expected to fund operations into at least H2 2026. R&D expenses decreased significantly to $24.8 million from $42.0 million in the prior year.

• Net loss for Q4 2024 was $29.4 million, an improvement compared to $46.8 million in Q4 2023.
• Cash, cash equivalents, and marketable securities totaled $252.9 million as of December 31, 2024, providing funding into at least H2 2026.

Seer reported a 10% decrease in Q4 2024 revenue to $4.0 million compared to the prior year, primarily due to lower instrument sales and no grant revenue. The company ended the year with approximately $300 million in cash, cash equivalents, and investments.

• Achieved revenue of $4.0 million for the fourth quarter of 2024.
• Shipped 10 instruments during 2024, bringing cumulative instruments shipped to 72.

WeightWatchers reported a decrease in total revenues and subscribers for the fourth quarter of fiscal year 2024 compared to the prior year. However, the company achieved significant growth in its Clinical business, with Clinical Subscription Revenues increasing by 57.9% and Clinical Paid Weeks by 53.3%. Profitability metrics such as Gross Margin, Operating Income, and Net Income showed substantial year-over-year improvements, driven by cost management initiatives.

• Total revenues for Q4 2024 were $184.4 million, a 10.5% decrease from the prior year period.
• The company reported a net income of $25.1 million for Q4 2024, a significant improvement from a net loss of $88.1 million in the prior year period.

Inuvo, Inc. delivered a strong performance in Q4 2024, achieving record revenue of $26.2 million, a 26% increase year-over-year. The company also reported positive net income of $141 thousand and adjusted EBITDA of $1.2 million, marking a significant improvement from losses in the prior year.

• Q4 2024 revenue reached a record $26.2 million, up 26% from Q4 2023.
• Net income for Q4 2024 was $141 thousand, a significant improvement from a net loss of $2.4 million in Q4 2023.

Energous Wireless Power Solutions reported a 62% increase in full-year revenue to $0.8 million in 2024, primarily driven by PowerBridge transmitter sales. The company also significantly reduced its non-GAAP operating expenses by 19% year-over-year and improved its net loss.

• Revenue for the full year ended December 31, 2024, increased by 62% to $0.8 million compared to $0.5 million in 2023.
• 88% of 2024 revenue was generated by the sale of PowerBridge transmitters, primarily PowerBridge PRO.

IMUNON reported a net loss for 2024 of $18.6 million, or $1.62 per share, compared with a net loss for 2023 of $19.5 million, or $2.16 per share. The company ended 2024 with $5.9 million in cash and cash equivalents.

• IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer.
• Patient enrollment in Phase 3 pivotal trial of IMNN-001 is scheduled to begin in Q1 2025.

BlackRock TCP Capital Corp. reported a net investment income of $0.40 per share for the fourth quarter of 2024. The board declared a first quarter dividend of $0.25 per share and a special dividend of $0.04 per share for 2025.

• Net investment income for Q4 2024 was $33.8 million, or $0.40 per share.
• Adjusted net investment income for Q4 2024 was $30.8 million, or $0.36 per share.